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ABSTRACT
Atherosclerosis is a slowly progressing disease characterized by the development of 
inflamed fatty deposits called atherosclerotic lesions or plaques within the innermost layer 
of the arterial wall, the intima. First subclinical atheromatous changes within the arterial 
intima begin early in childhood as a response to cholesterol accumulation and serve as 
precursors for more advanced lesions that develop during the following decades through 
complex series of cellular events. During the degenerative process of lesion formation, 
the affected arteries gradually lose their normal structure and function, and may become 
narrowed by the growing plaques, a process leading to impeded blood flow to end-organ. 
Eventually multiple subclinical cellular events may result in the development of unstable, 
vulnerable plaques that are prone to rupture culminating in the life threatening clinical 
manifestation of myocardial infarction or ischemic stroke. 
Atherosclerosis is strongly associated with lifestyle and age. Enhanced plasma level of 
low-density lipoprotein (LDL) is considered a definitive risk factor of atherosclerosis, 
emphasizing the crucial role of LDL in the process of lesion development. Circulating 
LDL particles are the major carriers of cholesterol to the arterial intima and their retention 
by subendothelial proteoglycans and subsequent modification within the intima drives 
intramural cholesterol accumulation and ensuing formation of atherosclerotic lesions. 
Another lipoprotein playing a central, yet opposite role in atherogenesis is the high 
density lipoprotein (HDL). HDL and its principal protein component, apolipoprotein A 
(apoA)-I, act against atherosclerotic lesion development by removing cholesterol from 
the arterial wall and delivering it to liver for excretion. In addition to this process referred 
to as reverse cholesterol transport, HDL and apoA-I possess various anti-inflammatory 
properties by which they may hinder the inflammatory processes involved in the plaque 
development, and thus to protect from the disease progression. However, similar to LDL, 
HDL within the arterial intima is subjected to various structural and compositional 
modifications that impair its normal physiological function leading to generation of 
HDL particles with reduced antiatherogenic properties. 
LDL and HDL modifications within the arterial intima can be induced by extracellular 
enzymes released from cells present in the intima. MCs are tissue-dwelling effector cells 
of innate and adaptive immunity that differentiate from committed circulating progenitor 
cells and are present in increased numbers in atherosclerotic lesions. Being capable of 
releasing large amounts of various neutral proteases upon activation, MCs are potential 
source of LDL and HDL proteolyzing enzymes. The aim of this thesis was to investigate 
the ability of various human MC neutral proteases to cleave the protein moieties of 
LDL and HDL particles, apoB-100 and apoA-I, respectively and thus to contribute to 
11
the pathogenic processes of LDL accumulation and inflammation both essential in 
development of atherosclerotic lesions.
In the present study, human MCs expressing four tryptase isoforms, chymase, 
carboxypeptidase A3, cathepsin G, and granzyme B are described. Of these, chymase 
and cathepsin G efficiently proteolyzed apoA-I and apoB-100, respectively generating 
C-terminally truncated apolipoproteins. Proteolysis by chymase resulted in reduced 
anti-inflammatory properties of apoA-I and impaired the ability of apoA-I to induce 
cholesterol efflux from macrophage foam cells. Furthermore, proteolysis of apoB-100 
by cathepsin G induced formation of fused LDL particles with increased binding to 
human aortic proteoglycans and atherosclerotic lesions of human carotid arteries. Taken 
together, the data presented in this thesis propose novel mechanisms by which human 
MC neutral proteases may promote lipid accumulation and inflammation within the 
arterial wall and thus promote lesion development and progression. 
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TIIVISTELMÄ
Ateroskleroosi (valtimonkovettumatauti) on suurten verisuonien eli valtimoiden 
sairaus, jossa valtimoiden seinämään kertyy rasvaa ja tulehdussoluja. Valtimoihin 
kerääntyvä rasva on pääosin kolesterolia, joka on peräisin low-density lipoproteiini 
(LDL)-hiukkasista. LDL on elimistön kemiallinen yhdiste, joka kuljettaa kolesterolia 
veren mukana sen synteesipaikasta maksasta muualle elimistöön, jossa solut käyttävät 
kolesterolia muun muassa kalvojensa rakennusaineeksi. Valtimoiden seinämään 
kolesteroli päätyy verenkierrosta kun LDL-hiukkanen läpäisee valtimon sisäpintaa 
verhoavan solukerroksen. Valtimon seinämän sisimmässä kerroksessa LDL jää kuitenkin 
kiinni seinämän soluväliaineen muodostamaan tiheään verkkoon, mikä estää hiukkasen 
poistumisen seinämästä. Seurauksena LDL-hiukkaset ja niiden sisältämä kolesteroli 
kerääntyvät valtimon seinämään.
Valtimon seinämässä LDL-hiukkasten tavanomainen rakenne ja koostumus ovat alttiita 
muokkaantumiselle, mikä edelleen vaikeuttaa niiden ulospääsyä seinämästä ja kiihdyttää 
LDL-kolesterolin kertymistä seinämään. Seurauksena syntyy krooninen tulehdusreaktio, 
joka johtaa vähitellen yhä suurempien kolesterolikertymien kehittymiseen. Koska 
kolesterolin kertyminen alkaa jo nuoruudessa ja etenee hitaasti vuosikymmenien 
kuluessa, ateroskleroosi kehittyy salakavalasti eikä yleensä aiheuta oireita ennen kuin 
kolesterolikertymät, niin kutsutut ateroskleroottiset plakit, kasvavat niin suuriksi, että 
ne alkavat ahtauttaa valtimoa haitaten hapekkaan veren kulkeutumista kohdekudokseen. 
Koska suurten tulehduksellisten plakkien pinta on pehmeää ja haurasta kudosta, se on altis 
repeytymään, jolloin paikalle muodostuu verihyytymä. Seurauksena on tavallisimmin 
joko aivo- tai sydäninfarkti.
Valtimonkovettumataudin kehittyminen on yhteydessä riskitekijöihin, joista useimmat 
liittyvät elintapoihin. Korkea veren LDL pitoisuus lisää valtimoon kerääntyvän 
kolesterolin määrää ja täten riskiä sairastua valtimonkovettumatautiin. Sen sijaan high-
density lipoproteiini (HDL)-hiukkasten pitoisuus veressä on kääntäen verrannollinen 
sairastumisriskiin. HDL:n suojaavan vaikutuksen ajatellaan perustuvan sen ja sen 
pääasiallisen proteiiniosan, apolipoproteiini (apo) A-I:n kykyyn poistaa kolesterolia 
valtimon seinämästä ja hillitä tulehdusreaktioita ateroskleroosin kehittymisen kannalta 
merkittävissä soluissa, minkä seurauksena ateroskleroottisten plakkien kehittyminen 
hidastuu. Ateroskleroosin kehittymisessä avainasemassa ovatkin siis kolesterolin 
kuljetushiukkaset LDL ja HDL, eikä niinkään kolesterolipitoisuus itsessään. Kuten LDL, 
myös HDL on kuitenkin altis muokkaantumaan valtimon seinämässä siten, että sen kyky 
suojata ateroskleroosilta heikkenee. 
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Syöttösolu on eräs ateroskleroottisissa plakeissa esiintyvä tulehdussolutyyppi, jonka 
on osoitettu osallistuvan ateroskleroosin kehittymiseen vapauttamalla aktivoiduttuaan 
proteiineja pilkkovia entsyymejä, niin kutsuttuja neutraaleja proteaaseja. 
Ateroskleroottisista plakeista löydetyt syöttösolut voidaan jakaa alatyyppeihin sen 
perusteella, mitä neutraaleja proteaaseja ne ilmentävät. Koska eri neutraaliproteaaseilla 
on kyky pilkkoa eri proteiineja, syöttösolujen alatyypeillä on mahdollisesti kliinistä 
merkitystä valtimonkovettumataudin kannalta. 
Tässä väitöskirjatyössä tutkittiin ihmisen verenkierrosta erilaistettujen syöttösolujen 
kykyä ilmentää eri neutraaliproteaaseja ja näiden proteaasien kykyä pilkkoa LDL- ja 
HDL-hiukkasten proteiiniosia, apoB-100:a ja apoA-I:a sekä tästä seuraavia mahdollisia 
ateroskleroosin kehittymisen kannalta merkityksellisiä vaikutuksia. Tutkimuksessa 
kuvataan ensimmäistä kertaa syöttösolutyyppi, joka ilmentää neutraaleihin proteaaseihin 
kuuluvia neljää erilaista tryptaasia sekä kymaasia, karboksipeptidaasi A3:a, katepsiin G:a 
ja grantsyymi B:a. Lisäksi tutkimuksen tulokset osoittavat, että näistä kymaasi pilkkoo 
HDL-hiukkasen apoA-I:a siten, että sen kyky poistaa valtimon seinämään kerääntynyttä 
kolesterolia sekä sen kyky estää valtimonkovettumataudin kannalta merkityksellisten 
solujen tulehduksellista aktivoitumista heikkenee. Tutkimuksessa havaittiin lisäksi, että 
katepsiini G pilkkoo LDL-hiukkasen apoB-100:a siten, että LDL-hiukkasten koko kasvaa 
ja niiden vuorovaikutus valtimon seinämän kanssa lisääntyy. Koska LDL-hiukkasten ja 
valtimon seinämän välinen vuorovaikutus on tärkeä ateroskleroosia edistävä tekijä, sen 
taustalla olevien mekanismien tunnistaminen tarjoaa mahdollisuuden uudentyyppisten, 
LDL-hiukkasten ja valtimonseinämän fysikaalisen vuorovaikutuksen estämiseen 
perustuvien hoitomuotojen kehittämiseen ateroskleroosin hoitoon. Lisäksi, koska apoA-
I:a proteolyyttinen pilkkoutuminen heikentää sen terapeuttista potentiaalia, tutkimuksen 
tulokset nostavat esille proteaasien aiheuttamalle pilkkoutumiselle vastustuskykyisten 
apoA-I:a matkivien molekyylien mahdollisen hyödyn tämän maailmanlaajuisesti 
merkityksellisen taudin hoidossa.
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INTRODUCTION 
Atherosclerosis is a degenerative disease of large- and medium-sized arteries characterized 
by focal development of cholesterol-rich, inflamed deposits, called atherosclerotic 
lesions or plaques, along the arterial tree. Development of atherosclerotic plaques causes 
hardening (loss of elasticity) of the artery and may lead to reduced blood flow to end 
organ, such as heart muscle or brain. Atherosclerosis is strongly associated with lifestyle 
and has a number of well-determined risk factors. These include hypertension, smoking, 
obesity, diabetes, lack of exercise, family history, high low-density lipoprotein cholesterol 
(LDL-C), low high-density lipoprotein cholesterol (HDL-C), and high triglycerides 
(TGs) (Lusis 2000, Fruchart et al., 2004). First morphological signs of atherosclerosis 
appear early in the childhood, after which the disease progresses silently for decades. 
Almost all people are affected to some degree by the age of 65, however symptoms, if 
any, occur only after narrowing of an artery (stenosis) impedes blood flow to end-organ 
enough to induce them. Continuous lipid accumulation and heightened inflammatory 
status may ultimately result in rupture of the atherosclerotic plaque fostering a formation 
of a blood clot that completely blocks the artery. Such acute event is the underlying 
cause of myocardial infarction and ischemic stroke, the leading causes of death globally 
(Benjamin et al., 2017).
The term ‘atherosclerosis’ is apparently first introduced by Felix Marchand in 1904 
and derives from the Greek “athera,” meaning gruel, or wax, corresponding to the 
porridge-like necrotic core area at the base of the atherosclerotic plaque, and “sclerosis” 
meaning hardening, referring to the fibrous cap of the plaque’s luminal edge. The first to 
demonstrate the role of cholesterol in the development of atherosclerosis was the Russian 
scientist Nikolai N. Anitschkov (1885-1964), whose classical experiments showed that 
feeding cholesterol to rabbits caused atheromatous changes in the arterial wall similar to 
what was found in humans [reviewed in (Konstantinov et al., 2006)]. Yet, an avalanche 
of research in cholesterol-induced atherosclerosis was produced by the identification in 
the mid-1950s that LDL-C is responsible for the rapid progression of atherosclerosis in 
humans (Gofman&Lindgren 1950). Nowadays it is widely accepted that the uptake into 
the vessel wall of LDL followed by LDL retention and modification within the arterial 
wall induce inflammatory responses that promote development of atherosclerotic 
lesions. Similarly, it has become obvious that HDL, the counter actor of LDL, protects 
from atherosclerosis by removing cholesterol from the arterial wall and by possessing 
various anti-inflammatory properties towards vascular and inflammatory cells.
Within the same decade that the role of LDL-C in atherosclerosis was elucidated, a 
tissue-dwelling inflammatory cell of hematopoietic origin, the mast cell (MC), was 
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first suggested to be involved in the susceptibility to experimental atherosclerosis. The 
hypothesis was proposed by Constantinides in 1953 based on his studies (Constantinides 
1953, Constantinides et al., 1953) suggesting that MCs, via heparin proteoglycan (PG) 
present in their granules, could be protective from atherosclerosis. Emerging number 
of studies in the following decades, however, gradually shifted the concept towards a 
pro-atherogenic role for MCs, as MC numbers in the different layers of the arterial wall 
were found to be increased with the progression of atherosclerosis (Atkinson et al., 1994, 
Kaartinen et al., 1994b, Kovanen et al., 1995, Jeziorska et al., 1997). 
MCs were originally discovered in 1877 by a medical student Paul Ehrlich, the later 
German scientist, who received the Nobel Prize in 1908 for his contributions to 
immunology [reviewed in (Crivellato et al., 2003)]. Ehrlich noticed that cells stained 
with aniline blue were full of cytoplasmic granules that had turned from a blue to 
a reddish color, a phenomenon referred to as metachromasia. Ehrlich believed that 
the granules were the result of overfeeding, and named the cells Mastzellen based on 
“mästen” in German, which refers to feeding. To date, MCs are best known as key 
effector cells mediating the immunoglobulin E (IgE)-dependent allergic reactions 
(Galli&Tsai 2012), however, potential roles for MCs at various stages of atherosclerosis 
have also been established (Kovanen 2007a, Bot et al., 2015). 
Human MCs have been traditionally classified into two major subtypes distinct in their 
granule protease composition. Originally the subtypes were found to differentially store 
two MC-specific neutral proteases, chymase and tryptase within their granules, and 
were thus termed as the MCT for an MC containing only tryptase and MCTC for an MC 
containing both tryptase and chymase (Irani et al., 1986, Irani et al., 1989). Both subtypes 
have been identified in atherosclerotic lesions (Kaartinen et al., 1994a, b), however, it 
has been a matter of debate, whether the phenotypes of these subtypes are precommited 
or whether they represent adaptation to different functional properties. Since many of 
the effector functions of MCs are attributed to their neutral proteases (Kovanen 2007b), 
which MCs release upon activation to extracellular microenvironment, the existence of 
tissue MCs with different combinations of proteases having different peptide and protein 
targets, may be of clinical importance. The aim of this study was to clarify the concept 
of the heterogeneity and plasticity of human MC phenotypes by investigating protease 
expression in cultured human MCs and to investigate the ability of the expressed neutral 
proteases to contribute to atherogenesis via proteolyzing the major protein moieties of 
LDL and HDL particles.
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REVIEW OF THE LITERATURE 
1 Atherosclerosis and plasma lipoproteins  
It has been over a century since the concept of atherosclerosis as a cholesterol-driven 
disease was introduced [reviewed in (Konstantinov et al., 2006)]. During the following 
decades, it has been discovered that the key sources of cholesterol in the atherosclerotic 
lesions are apolipoprotein B (apoB)-containing lipoproteins from plasma. There is 
now vast evidence—from epidemiology, genetics (including Mendelian randomization 
studies), experimental models, and clinical trials—to prove that the role of cholesterol-
rich apoB-containing lipoproteins in the pathogenesis of atherosclerosis is fundamental 
and causative (Ference et al., 2017). Indeed, the direct link between plasma cholesterol 
of apoB-containing lipoproteins and atherosclerosis is emphasized by the success of 
cholesterol-lowering drugs in the treatment of atherosclerosis. 
The apoB-containing lipoproteins comprise various particles that can be separated by 
ultracentrifugation into different subclasses based on their buoyant densities. These 
subclasses are in the order of decreasing size and increasing density, chylomicrons, 
very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and LDL 
(Figure 1). Of these, LDL is the principal driver of atherosclerotic plaque development. 
A non-apoB-containing lipoprotein, HDL, plays also a crucial, yet opposing, role in 
atherosclerosis. HDL is regarded as anti-atherogenic, mainly because of its role in cellular 
cholesterol extraction (Navab et al., 2011), which hinders cholesterol accumulation 
within arterial walls. It has become obvious, however, that the relationship between HDL 
and atherosclerosis is more complex than that between LDL and atherosclerosis (Rohatgi 
2015). The following sections describe the structural and compositional characteristics 
of LDL and HDL, the two lipoprotein subclasses most relevant in the pathobiology of 
atherosclerosis, as well as their roles in the development of atherosclerotic lesions, the 
process referred to as atherogenesis.
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Chylomicron VLDL IDL LDL HDL
Diameter (nm) 1000 35–90 25–35 20–25 10
Density (g/ml) <0.95 <1.006 1.006–1.019 1.019–1.063 1.063–1.210
Average blood level (mM)* N/A 0.1 –0.7 N/A 2.6–3.9 1.3–2.0
Source Intestine Liver VLDL 
catabolism
IDL 
catabolism
Liver, 
intestine
TAG (%) 86 55 31 6 4
CE (%) 3 12 23 42 12–20
UC (%) 2 7 7 8 4
PL (%) 7 18 22 22 25–30
Protein (%) 2 8 15 22 44–50
Major
apolipoproteins
ApoB-48
ApoC-I, -II, III
ApoE
ApoB-100
ApoC-I, -II, III
ApoE
ApoB-100
ApoE
ApoB-100 ApoA-I, -II, -IV
ApoE
Figure 1. Plasma lipoproteins of various subclasses. Human plasma lipoproteins are macromolecular complexes 
that transport hydrophobic lipids between tissues through the circulatory system. Mature plasma lipoproteins 
are spherical particles composed of a hydrophobic core formed by triacylglycerols and cholesteryl esters, and a 
monolayer of amphipathic phospholipids, unesterified cholesterol, and apolipoproteins. Different combinations 
of apolipoproteins and lipids produce lipoprotein particles with different densities that can be separated by 
ultracentrifugation into various subclasses. The major plasma lipoprotein subclasses in humans include, in the order 
of increasing densities and decreasing size, chylomicrons, VLDL, IDL, LDL, and HDL. Each lipoprotein subclass has 
a unique role determined by its site of origin, lipid composition, and apolipoprotein content. N/A, not available. The 
chylomicrons contain C-terminally truncated apoB, apoB-48, and carries dietary lipids from intestine to liver. 
The apoB-100-containing lipoprotein VLDL carries lipids of hepatic origin to extrahepatic tissues and gives rise 
to LDL via IDL through a metabolic cascade in the circulation. LDL is the major cholesterol carrier of human 
plasma and drives atherogenesis by promoting cholesterol accumulation within the arterial wall. HDL is an 
apoA-containing lipoprotein, which carries cholesterol from the extrahepatic tissues back to liver for excretion, 
and is thus regarded as anti-atherogenic. *Values vary depending on age, sex, and life style. (%) of dry weight. 
Data from (Chapman 1986, Havel&Kane 2001, Jonas 2002, Langsted et al., 2008). CE, cholesteryl ester; N/A, 
not available; PL, phospholipid; TAG, triacylglycerol; UC, unesterified cholesterol.
VLDL
 35–90 
<1.006
ApoB-100
ApoC-I, -II, -III
ApoE
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cholesteryl ester  phosphatidylcholine
triglyceride sphingomyelin
cholesterol apoB-100 protein
1.1 Low-density lipoprotein 
Human plasma LDL particles are spherical particles with the average size of 22 nm in 
diameters and density ranging from 1.019 to 1.063 g/ml (Lindgren et al., 1951, Havel et 
al., 1955, Hevonoja et al., 2000). The physiological role of LDL is to provide cholesterol for 
cells of extrahepatic tissues, which bind and internalize LDL via their plasma membrane 
receptors (Brown&Goldstein 1986). LDL is produced through a metabolic cascade in the 
circulation from VLDL, which again is synthesized in the liver (Robinson 1973). From 
the liver VLDL is secreted into the circulation, where endothelial lipoprotein lipase in the 
capillaries of muscle and adipose tissues releases free fatty acids from the triacylglycerols 
(TAGs) present in the VLDL core (Robinson 1973, Chapman et al., 2011). In addition, 
some of the surface lipids and apolipoproteins (C and E) of VLDL are transferred to 
HDL, in a process mediated by lipoprotein lipase and lipid transfer proteins in plasma 
(Tall 1995, Murdoch&Breckenridge 1996, Chapman et al., 2011). VLDL remnants remain 
in the blood and are converted first into IDLs and further into LDLs, in a process that 
involves hepatic lipase (Demant et al., 1988, Chapman et al., 2011). As a resultant particle 
of such metabolic cascade, LDL contains much less TAGs than VLDL, but, instead is 
very rich in cholesteryl esters (CEs). In addition, due to removal of apoCs and apoE 
from VLDL to HDL, LDL contains apoB-100 as virtually its sole apolipoprotein. The 
composition of LDL is portrayed in Figure 2. 
Figure 2. Composition of LDL particle. LDL is composed of a hydrophopic core of neutral lipids consisting of 
approximately 1600 molecules of cholesteryl esters and 170 molecules of triacylglycerols. The surface monolayer 
consists of about 700 molecules of phospholipids and a single copy of apoB-100. In addition, one LDL particle 
contains, on average, 600 molecules of unesterified cholesterol, of which approximately one third lies in the core 
and two thirds reside on the surface. The main phospholipid components of LDL are phosphatidylcholine and 
sphingomyelin, which constitute about 70% and 30% of the phospholipids, respectively. In addition, one LDL 
particle contains, on average, 80 molecules of lysophosphatidylcholine, 10 molecules of phosphatidylethanolamine, 
7 molecules of diacylglycerol, molecules of ceramide, and some phosphatidylinositol molecules. Data from (Lund-
Katz&Phillips 1986, Esterbauer et al., 1992, Hevonoja et al., 2000). Image modified from (Hevonoja et al., 2000) 
with the permission of the copyright holder.
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1.2 Apolipoprotein B-100 
ApoB-100 is a large protein that envelopes the surface of pro-atherogenic lipoproteins 
of hepatic origin (VLDL, IDL, and LDL). In addition, lipoprotein(a) [Lp(a)], a unique 
lipoprotein contains apoB-100 to which apo(a), a member of the plasminogen gene 
family has been covalently attached (Anuurad et al., 2006). Consisting of 4536 amino 
acid residues (Chen et al., 1986, Knott et al., 1986) and with a molecular mass of about 
550 kDa for the glycosylated form (Knott et al., 1986), apoB-100 is one of the largest 
monomeric proteins known (Chen et al., 1986). ApoB-100 is synthesized in the liver, from 
where it is secreted together with VLDL (Schaefer et al., 1978). ApoB-100 contains many 
hydrophobic regions some of which are extensive and associate tightly with lipids (Chen 
et al., 1989, Yang et al., 1989). The lipid binding structures in the form of amphipathic 
α-helices, β-strands, and hydrophobic regions span throughout the length of apoB-100 
and consequently, unlike other apolipoproteins (C and E), apoB-100 binds irreversibly 
to the VLDL surface and does not exchange with other lipoprotein particles (Schaefer 
et al., 1978). Thus, apoB-100 remains bound to the shrinking particle throughout the 
metabolic cascade of transforming VLDL to LDL (Schaefer et al., 1978). 
Each LDL particle contains a single copy of apoB-100, which has been suggested to be 
responsible for particle integrity by wrapping around the surface of LDL acting as a 
macromolecular scaffold (Chatterton et al., 1991, Chatterton et al., 1995, Liu&Atkinson 
2011). However, rather than encircling an LDL particle in a straightforward manner, 
apoB-100 forms kinks and can be described as having a “ribbon and bow” configuration 
(Chatterton et al., 1995). According to this model the N-terminal 89% of the peptide 
wraps around the LDL as a thick “ribbon”, completing the encirclement by about amino 
acid residue 4050, and the C-terminal 11% of the peptide constitutes the “bow” crossing 
the ribbon (Chatterton et al., 1995). 
In addition to its suggested structural role, apoB-100 has a physiologically important 
function serving as a ligand for the LDL receptor (LDLR). Binding of apoB-100 to LDLR 
on the target cells initiates receptor-mediated uptake of LDL, the underlying mechanism 
of LDL clearance from circulation by hepatocytes (Brown et al., 1981). The relevance of this 
catabolic pathway is best illustrated by the genetic disorder familial hypercholesterolemia 
(FH), characterized by accumulation of high levels of LDL in the circulation due to 
mutations in the LDLR gene that hinder receptor-mediated clearance of plasma LDL 
(Defesche et al., 2017). The physiological upper limit for plasma LDL cholesterol (LDL-C) 
concentration has been suggested to be 1.5 mmol/l (Goldstein&Brown 1977), whereas 
in patients with the heterozygous form of FH plasma LDL-C level ranges from about 5 
to 10 mmol/l and in the more severe homozygous form of FH, it may be as high as 30 
mmol/l (Nordestgaard et al., 2013). Consequently, patients with FH have increased risk 
of premature development of atherosclerotic plaques. 
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The confirmation for the principal LDLR-binding site in apoB-100 came from studies of 
Borén and coworkers using site-directed mutagenesis of apoB-100 (Boren et al., 1998a) to 
indicate that the LDLR-binding site is formed by a cluster of basic amino acids spanning 
the residues 3359–3369 (termed as Site B). Accordingly, when the basic amino acids in 
the Site B were changed to neutral amino acids, LDL particles containing the uncharged 
Site B had defective receptor-binding indicating that Site B is functionally important for 
LDLR binding (Boren et al., 1998a). The group also showed that the highly conserved 
receptor-binding site is stabilized by the interaction of Arg3500 with Trp4369, and that 
a single point amino acid mutation, namely Arg3500 to Gln3500, completely abolishes 
interaction of LDL with the receptor (Boren et al., 1998a). This was shown to result from 
blocking of the LDLR-binding site by the C-terminus of apoB-100, which is kept away 
from the binding site by Arg3500 in wild-type LDL (Boren et al., 1998a). Because apoB-
100 binds to the LDLR only after the conversion of VLDL to LDL, it is proposed that, 
in VLDL, the C-terminus normally functions to inhibit the interaction of apoB-100 
with the LDLR, but after the conversion of VLDL to LDL, Arg3500 interacts with the 
C-terminus, permitting normal interaction between LDL and its receptor (Boren et al., 
1998a). The Arg3500 to Gln3500 mutation in apoB-100, and to a lesser extent Arg3500 to 
Trp3500, is known to lead to a disorder known as familial defective apoB, where defective 
binding of apoB-100 to LDLR impairs LDL clearance from the circulation causing 
hypercholesterolemia in a similar manner to FH (Andersen et al., 2016). 
ApoB-100 also mediates interaction of LDL with the arterial wall by binding to arterial 
PGs (Camejo et al., 1998). Interestingly, the principal PG-binding site appears to be 
formed by the same amino acid residues that form the LDLR-binding site (Boren et 
al., 1998b). The PG-binding ability of LDL has gained a vast interest in the context of 
atherosclerosis (Tabas et al., 2007, Boren&Williams 2016), as discussed in later sections.
1.3 High-density lipoprotein
HDL particles are the smallest and the densest lipoprotein particles of human plasma. 
The physiological role of HDL is opposite to that of LDL, thus, HDL removes cholesterol 
from the peripheral tissues and delivers it to liver for excretion into feces, a process 
referred to as reverse cholesterol transport (RCT) (Glomset 1968). Human plasma HDL 
constitutes a heterogeneous group of particles ranging 7–12 nm in diameter and 1.063–
1.21 g/ml in density (Figure 3). By ultracentrifugation, these particles can be separated 
into two subfractions on the basis of their buoyant densities: HDL2 (1.063-1.125 g/ml) 
and HDL3 (1.125-1.21 g/ml) (Havel et al., 1955). These subspecies can be further divided 
in decreasing order of a particle diameter into HDL2b, HDL2a, HDL3a, HDL3b, and 
HDL3c with average diameters of 10.6, 9.2, 8.4, 8.0, and 7.6 nm, respectively (Blanche 
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et al., 1981). The calculated lipid composition of an HDL2 particle is on average 137 
molecules of phospholipids (PL), 50 molecules of unesterified cholesterol (UC), 90 
molecules of CE, and 19 molecules of TAG, whereas each HDL3 particle contains on 
average 51 molecules of PL, 13 molecules of UC, 32 molecules of CE, and 9 molecules of 
TAG (Shen et al., 1977). 
On the basis of electrophoretic mobility human plasma HDL particles can be separated 
into two main subpopulations: spherical α-HDL particles, which have the same mobility 
as α-globulin and discoidal pre-β HDL particles, which are the precursors for the 
spherical α-HDL particles and migrate similarly to pre-β globulin (Kunitake et al., 1985, 
Castro&Fielding 1988). Two-dimensional electrophoresis allows further separation by 
charge and size of discoidal very small pre-β1, large pre-β2 and -β3, small discoidal α4, 
small spherical α3, medium-sized spherical α2, and large spherical α1 (Asztalos et al., 
2005, Camont et al., 2011, Rosenson et al., 2011). 
HDL can also be separated on the basis of apolipoprotein composition into several 
subpopulations using immunoaffinity methods (Hennessy et al., 1993). ApoA-I is 
the principal apolipoprotein of HDL particles comprising approximately 60–70% of 
total plasma HDL protein, with the second most abundant apolipoprotein, apoA-II, 
comprising about 20%  (Huang et al., 2011). In human plasma, about 25% of apoA-I is 
present in HDL particles containing only apoA-I (LpA-I); the remaining HDL particles 
contain both apoA-I and apoA-II (LpA-I+A-II), typically in a molar ratio of 1-2/1 
(Gauthamadasa et al., 2010). Moreover, a minor subpopulation of large, spherical HDL 
particles migrating to γ-position contain apoE as the only apolipoprotein (Huang et 
al., 1994). Other apolipoproteins that have been associated with HDL particles include 
apoA-IV, and –V, apoC-I, -II, -III, and –IV, apoD, apoF , apoH, apoJ, apoL-I, and apoM 
[summarized in (Rosenson et al., 2011)]. 
Altogether, over 200 lipid species and over 80 different proteins, including the HDL 
remodeling proteins cholesteryl ester transfer protein (CETP) and lecithin:cholesterol 
acyltransferase (LCAT), the HDL oxidizing protein myeloperoxidase, the antioxidant 
protein paraoxonase1, and protease inhibitors (antithrombin III, α-1-antitrypsin 
inhibitor, serine protease inhibitors) have been proposed to be associated with HDL 
(Toth et al., 2013). Thus, hundreds of different HDL subspecies based on their individual 
protein and lipid composition is likely to be present in human plasma. However rather 
than representing static pools of distinct particles, they reflect the dynamic nature of 
HDL resulting from continuous remodeling, lipolysis, and fusion that can convert smaller 
particles to larger particles and vice versa, as will be discussed in the section  1.3.2. 
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HDL2 HDL3
A
Discoidal Spherical
B
HDL2b HDL2a HDL3a HDL3b HDL3c
C 10.6 7.6
1.063 1.21
Diameter (nm)
Densitv (g/ml)
>80 proteins and
hundreds of lipid species
preβ-1 preβ-3
preβ-2
LpA-I LpA-I/A-II
α-migration
Discoidal HDL
preβ-migration γ-migration
LpE
Lipid-free apoA-I
Lipid-free apoA-II
α-1 α-2 α-3 α-4
Figure 3. HDL heterogeneity and complexity. HDL particles in human plasma consist of various subclasses that 
can be distinguished based on shape (A), size (B), density (C), apolipoprotein and lipid composition (D), and 
electrophoretic mobility (E). Modified from (Rye et al., 2009) with the permission of the copyright holder.
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1.3.1 Apolipoprotein A-I
ApoA-I is the principal protein component of HDL particles. Human apoA-I is a 28 kDa 
protein consisting of 243 amino acids (Brewer et al., 1978, Breslow et al., 1982) and is 
made up of repeating amphipathic α-helices that reversibly bind it to the surface of HDL 
particles (Segrest et al., 1992). Indeed, in contrast to apoB-100, apoA-I is an exchangeable 
apolipoprotein capable of transitioning between lipid-bound and lipid-free states. The 
majority of circulating apoA-I is bound to HDL particles, whereas approximately 5–10% 
of apoA-I in the serum or extracellular space has been estimated to be relatively lipid free 
(Neary&Gowland 1987). The apoA gene is expressed in the liver and intestine (Zannis et 
al., 1982, Eisenberg 1984) and locates on chromosome 11 as a is part of the APOA1/C3/ 
A4/A5 multigene cluster (Karathanasis 1985). The protein contains two key domains, an 
N-terminal α-helix bundle that spans residues 1 to 189 and a separately folded C-terminal 
domain spanning the remainder of the protein (Saito et al., 2003). Of these, the C-terminal 
domain is more hydrophobic and has higher lipid affinity compared with the N-terminus 
(Saito et al., 2004). ApoA-I plays crucial roles in HDL metabolism and RCT through its 
interaction with ATP-binding casette transporter A1 (ABCA1), activating LCAT, and acting 
as a ligand for hepatic scavenger receptor class B type 1 (SR-B1) (Mei&Atkinson 2015).
1.3.2 HDL metabolism and reverse cholesterol transport
The first step in the formation of HDL is the biogenesis of nascent discoidal HDL 
through efflux of cellular lipids to extracellular lipid-free or lipid-poor apoAI in a process 
mediated by ABCA1 (Wang&Smith 2014). The esterification of cholesterol through the 
action of the enzyme LCAT then leads to building up the hydrophobic core transforming 
the discoidal particles into spherical particles that represent the bulk of circulating HDL 
(Francone et al., 1989). The growing particles can accept additional cellular cholesterol 
through the activities of cellular ABCG1 (Wang et al., 2004) and SR-BI (Ji et al., 1997). 
Finally, the CEs in HDL are returned to the liver directly via hepatic uptake by SR-BI, or 
indirectly via transfer by CETP of CEs to VLDL and LDL, which then deliver CEs to liver. 
In the liver, the CEs can be converted to UC for direct excretion or converted to bile acids 
for excretion, completing the RCT pathway. 
HDL particles are continuously remodeled in plasma by various proteins that determine 
the concentration, composition, and size of plasma HDL particles (Table 1). In addition to 
ABCG1, SR-B1, CETP these include phospholipid transfer protein (PLTP) that exchange 
lipids between HDL and other lipoproteins, and various lipases (lipoprotein lipase, 
endothelial lipase, and hepatic lipase) that hydrolyze HDL lipids. During the remodeling of 
HDL in plasma lipid-free apoA-I is continuously being regenerated, thus the assembly of 
HDL in the circulation may have a significant contribution to the total plasma HDL pool.
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Table 1. Proteins involved in HDL metabolism and remodeling
Protein Function HDL conversion
Cholesterol transporters
ABCA1 Transfers PL and UC to apoA-I apoA-I > discoidal
ABCG1 Transfers UC to HDL Spherical > larger spherical
SR-B1 Transfers UC to HDL Spherical > larger spherical
Enzymes
Endothelial lipase Hydrolyzes PLs (and to a lesser extent TAGs) Spherical > small spherical
Hepatic lipase Hydrolyzes PLs and TAGs Spherical > small spherical + free apoA-I
LCAT Generates CEs Discoidal > spherical
Lipid transfer proteins
CETP Transfers CEs and TAGs between HDL, LDL, and VLDL
Spherical > small spherical 
+ free apoA-I
PLTP
Transfers PLs between HDL a
nd VLDL and between individual HDL 
particles
Spherical > large spherical 
and small spherical 
+ free apoA-I
1.4 Pathophysiology of atherosclerosis
After analysis of the data from the Framingham study (Dawber et al., 1957), LDL-C, TG 
and HDL-C emerged as strong independent predictors of atherosclerosis, and remain 
to date the cornerstone in risk estimation for future atherosclerotic events. Increased 
plasma LDL-C and reduced HDL-C levels drive atherogenesis by promoting cholesterol 
accumulation within the arterial wall (Stamler et al., 1986). It has been reported that 
lipoproteins up to approximately 70 nm in diameter can cross an intact endothelium 
(Nordestgaard&Zilversmit 1988), and among these the smaller ones pass more readily 
than the larger ones. Thus circulating LDL (~ 20 nm) and HDL (~ 10 nm) can efficiently 
penetrate the endothelial cell (EC) lining of the artery wall (Stender&Zilversmit 1981, 
Nordestgaard et al., 1992) and thus to enter the innermost layer of the arterial wall, the 
intima. The smaller HDL particles also efficiently exit the intimal layer, whereas the larger 
LDL particles are more easily trapped within the intima, a phenomenon which promotes 
their intramural accumulation, and initiates series of events leading to atherosclerotic 
lesion formation  (Williams&Tabas 1995, Tabas et al., 2007). The earliest recognizable 
gross lesions in the pathogenesis of atherosclerosis are called the fatty streaks (Stary et al., 
1994), characterized by the appearance within the intima of cells, mainly macrophages 
Data from (Ji et al., 1997, Wang et al., 2004, Rye&Barter 2014, Wang&Smith 2014)
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but also smooth muscle cells (SMCs), with high amounts of large intracellular CE-rich 
lipid droplets (Haley et al., 1977, Gerrity et al., 1979, Gerrity&Naito 1980, Schaffner et 
al., 1980). Such lipid-laden cells appear foamy in the electron microscope and are thereby 
referred to as foam cells (Takebayashi et al., 1972). As the atherogenic process proceeds, 
the continuous lipid accumulation and a complex series of cellular events gradually lead 
to development of more advanced lesions, which may ultimately predispose to clinical 
complications (Stary et al., 1994, Stary et al., 1995).
1.4.1 Humoral and parietal factors promoting atherogenesis
Although the central role of LDL in atherogenesis cannot be overstated, several other 
humoral and parietal factors are required to initiate and maintain the atherogenic 
process within arterial intima. Intima comprises the luminal endothelium and the 
underlying connective tissue and is composed of two layers: 1) a subendothelial PG-rich 
layer containing SMCs mainly of the synthesizing phenotype as well as isolated tissue 
macrophages near the endothelium, and 2) a deeper musculoelastic layer rich in collagen, 
elastic fibers, and layers of SMCs of the contractile phenotype (Stary et al., 1992). The 
intima is separated by an internal elastic lamina from the media, the middle layer of 
highly ordered structure of contractile SMCs layered within elastic fibers and collagen. 
Finally, the outermost layer surrounding the media, called the adventitia, is composed of 
loose connective tissue and hosts lymphatic veins and small blood vessels, vasa vasorum, 
through which nutrients and metabolic waste flux to and from the arterial wall (Nakano 
et al., 2005).
Within the intima LDL metabolism differs from that of other tissues. This difference 
is due to specific structural characteristics of intima, mainly the lack of capillaries and 
lymphatics within intima (Hulten&Levin 2009). As a consequence, the level of LDL-C 
within intima is 10-fold higher compared with other tissues (Smith 1990), which makes 
intima especially susceptible for development of atherosclerotic plaques.
Studies of the early events of atherogenesis have shown that lipoprotein accumulation in 
the arterial intima occurs preferentially at sites known to be susceptible for later plaque 
development (Schwenke&Carew 1989a, b, Nakashima et al., 2007). Such prelesional but 
lesion-prone sites are located preferentially at branch points and curvatures of the arterial 
tree (Stary et al., 1992). The altered hemodynamic parameters, such as low shear stress 
and disturbed flow at these sites are intrinsically linked to vascular endothelial phenotype 
and inflammation via activation of ECs and upregulation of adhesion molecules on their 
surface (Gimbrone&Garcia-Cardena 2013, Tabas et al., 2015). These adhesion molecules 
trigger the migration of circulating inflammatory cells to the subendothelial space (Rao 
et al., 2007). The same hemodynamic factors lead to changes in endothelial function in a 
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manner that impairs atheroprotective functions. Furthermore, physiological adaptation 
of the arterial wall to the altered hemodynamic forces at the lesion prone sites cause 
intimal thickening (Stary et al., 1992, Tabas et al., 2015). Thickened intima increases the 
transit distance of LDL to adventitial lymphatics or back to the vessel lumen (Kovanen 
1990). Furthermore, proliferation of extracellular matrix (ECM) molecules, especially 
PGs that are capable of binding to and trapping LDL within the arterial wall, likely 
renders these sites especially prone to lesion formation (Stary et al., 1992, Nakashima et 
al., 2007, Steffensen et al., 2015). 
1.4.2 Subendothelial retention of LDL within the arterial wall
Several lines of evidence support the concept that the underlying mechanism of 
cholesterol accumulation and thus initiation of atherogenesis is the focal retention of LDL 
by subendothelial PGs within the arterial intima (Boren&Williams 2016). The concept 
was extensively studied by Camejo and co-workers [reviewed in (Camejo et al., 1980a)] 
and reinforced later by Williams and Tabas in their ‘response to retention’ hypothesis of 
atherosclerosis (Williams&Tabas 1995, Tabas et al., 2007, Boren&Williams 2016), which 
was promoted by numerous in vitro and in vivo studies both in human and experimental 
animals. Such studies have shown that apoB-100-containing lipoproteins from plasma 
can interact in vitro with PGs extracted from the aortic wall (Bihari-Varga&Vegh 1967, 
Iverius 1972, Camejo et al., 1975, Camejo et al., 1980b, Vijayagopal et al., 1981) and that 
complexes of lipoproteins and PGs are also present in vivo in human atherosclerotic 
lesions (Srinivasan et al., 1972, Srinivasan et al., 1975, Camejo et al., 1985, Nakashima et 
al., 1985). Furthermore early LDL deposits are found in the arterial intima of experimental 
animals and precede further plaque development (Mora et al., 1987, Frank&Fogelman 
1989, Nievelstein et al., 1991). Within the intima such accumulated lipoproteins are 
present enmeshed in the dense ECM (Frank&Fogelman 1989). Consistent with the 
studies in experimental animals Nakashima and coworkers (Nakashima et al., 2007) 
have indicated that human atherosclerosis begins with extracellular deposition of apoB-
containing lipoproteins in the outer layer of the pre-existing adaptive intimal thickening 
rich in PGs. 
Recent support for the importance of lipoprotein retention in atherogenesis has come from 
experimental studies in hypercholesterolemic animals [reviewed in (Boren&Williams 
2016)]. In such studies interventions were performed that did not change plasma 
concentration of apoB-containing lipoproteins but specifically decreased or increased 
the retention of these particles within the arterial wall. Consequently, corresponding 
decrease or increase in atherogenesis was observed.  
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1.4.2.1 Molecular mechanisms of LDL retention
The interaction of PGs and LDL is ionic in nature and occurs between the negatively charged 
GAG chains and the positively charged amino acid residues, such as Lys and Arg, of apoB 
(Camejo et al., 1998, Chait&Wight 2000). To date, at least eight potential binding sites for 
PGs have been identified in vitro, most of them close to the C-terminal end of the protein 
(Camejo et al., 1998). However, it is suggested that most of them may not be functionally 
available on LDL. Supporting this hypothesis, Borén and coworkers (Boren et al., 1998a) have 
shown that the binding of LDL particles to PGs is severely impaired by mutation of Lys3363 
to Glu3363 (Boren et al., 1998a), thus implying that the apoB-100 in LDL contains only a 
single crucial PG-binding site, that is the amino acid residues 3359–3369 (referred to as Site 
B). Experimental studies have provided evidence that specific arterial wall PGs, particularly 
those containing chondroitin sulfate (CS) side chains have an important role in apoB-
containing lipoprotein retention and atherosclerosis (Williams 2001, Gustafsson&Boren 
2004). Furthermore, purified arterial CSPGs, particularly from lesion-prone sites, have high 
affinity for LDL (Cardoso&Mourao 1994, Ismail et al., 1994). The major CSPGs in the ECM 
of the mammalian arterial wall are versican, decorin and biglycan, and of these, apoB shows 
the strongest colocalization with biglycan (O'Brien et al., 1998).
While LDL retention within the arterial wall is initially related to direct binding between 
LDL and subendothelial PGs (Boren et al., 1998a, Skålen et al., 2002), indirect binding 
via accessory molecules acting as a ‘bridge’ between LDL and arterial matrix appears to 
govern as lesions progress (Gustafsson et al., 2007). Indeed, a series of studies in mice 
expressing apoB-100 with site directed mutations in its GAG-binding domain (Boren et 
al., 1998a, Skålen et al., 2002) demonstrated that the mutation in apoB-100 caused weak 
binding of the mutated apoB-containing LDL to PGs. The results showed convincingly 
that mice expressing the PG-binding–defective LDL had greatly reduced atherogenesis 
and that this effect was indeed due to decreased interaction of the mutated LDL with 
arterial wall PGs (Skålen et al., 2002).  Further studies in such mice expressing the 
PG-binding defective LDL showed that although the initiation of atherosclerosis was 
delayed in these mice, they eventually developed the same level of atherosclerosis as mice 
expressing control LDL (Gustafsson et al., 2007). This was due to infiltration of the intima 
by macrophages that secrete bridging molecules, such as lipoprotein lipase that facilitate 
LDL adherence to arterial matrix. Such bridging molecules work together in sync with 
other possible proatherogenic mechanisms such as alterations in PG synthesis, including 
that mediated by lesional macrophages (Chang et al., 1998, Maor et al., 2000), presence 
of lesion-specific LDL-binding proteins (Lees et al., 2005), pro-retentive modifications of 
LDL (Auerbach et al., 1996, Pentikäinen et al., 2000, Plihtari et al., 2010), and decrease 
in intimal pH (Sneck et al., 2005, Lähdesmäki et al., 2012) culminating in enhanced 
retention of atherogenic lipoproteins. Indeed, once early lesions appear, lipoprotein 
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retention is accelerated (Schwenke&St Clair 1992), which is likely to further promote 
lipid accumulation and lesion development. 
1.4.3 Modifications of LDL hinder their exit from the arterial wall
Characterization of extracellular lipid particles isolated from atherosclerotic intima have 
provided evidence that the retained LDL particles within arterial intima are subjected 
to various enzymatic and nonenzymatic modifications such as proteolysis, lipolysis, 
and oxidation (Öörni et al., 2000). In vitro such modifications have shown to promote 
aggregation and fusion of LDL particles, as described in the next sections, generating 
enlarged lipid particles with increased PG-binding properties. Morphologically and 
chemically such in vitro generated modified LDL particles resemble those found 
extracellularly within the atherosclerotic intima (Smith et al., 1967, Smith et al., 1968, 
Hoff&Bond 1982, Ylä-Herttuala et al., 1990, Öörni et al., 2000, Lehti et al., 2018). It has 
become obvious that modification of LDL particles is an important step in atherogenesis 
promoting both extracellular and intracellular lipid accumulation within the arterial 
wall (Öörni et al., 2000, Tabas et al., 2007, Lu&Gursky 2013). Moreover, the retained and 
modified LDL particles trigger various proinflammatory responses in the vessel wall which 
further promote lesion formation (Pentikäinen et al., 2000, Boren&Williams 2016).
1.4.3.1 Oxidation
Oxidized LDL (oxLDL) is present in plasma and in atherosclerotic lesions, both in 
experimental animals and in humans (Haberland et al., 1988, Ylä-Herttuala et al., 1989, 
Steinberg 2009). Oxidation of LDL is a complex process during which both the protein 
and lipid components may undergo oxidative changes at various degrees. Various cell 
types present in atherosclerotic lesions, such as ECs, SMCs, and monocytes produce free 
radicals that are able to oxidize LDL (Heinecke et al., 1984, Morel et al., 1984, Cathcart et 
al., 1985). LDL oxidation by cultured cells is promoted by the presence of transition metal 
ions such as Cu+ and Fe2+ in the culture medium, however, metal ions can oxidize LDL 
even in the absence of cells (Heinecke et al., 1984, Steinbrecher et al., 1984). Whether 
metal ions play a role in LDL oxidation in vivo is, however, still a matter of debate 
(Yoshida&Kisugi 2010). The heme released from red blood cells is capable of oxidizing 
LDL in vitro and could be a potential oxidative agent also in vivo (Grinshtein et al., 2003). 
LDL oxidation can also be mediated via oxidizing enzymes such as lipoxygenase and 
myeloperoxidase (Yoshida&Kisugi 2010). 
Due to the wide-ranging and complicated mechanisms of oxidation, oxLDL exists in 
multiple forms. Depending on the method and extent of oxidation as well as the presence 
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of other agents such as metal ions, oxLDL may contain various amounts of oxidative fatty 
acid derivatives both in the ester and free forms as well as their decomposition products, 
oxidized products of cholesterol, protein with oxidized amino acids and cross-links, and 
polypeptides with varying extents of covalent modification with lipid oxidation products. 
Malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) are natural bi-products of lipid 
peroxidation that can oxidize LDL. The corresponding modified LDL particles, MDA- and 
4-HNE –LDL are known to occur in vivo (Lampka et al., 2006, Takamura et al., 2017). The 
multiple forms of oxLDL exhibit a wide array of proatherogenic properties. These include 
induction of foam cell formation, cytotoxicity, chemotactic activity for monocytes, ability 
to increase expression of  VCAM-1, and ability to induce expression and secretion of a 
wide variety of proinflammatory cytokines from macrophages (Steinberg 2009).
1.4.3.2 Lipolysis and proteolysis
Within atherosclerotic arterial intima, two types of phospholipolytic enzymes, the 
secretory phospholipase A2 enzymes (sPLA2) and the secretory sphingomyelinase 
(sSMase), capable of hydrolyzing the surface PLs of LDL particles have been detected 
(Öörni et al., 2000, Hanasaki et al., 2002, Wooton-Kee et al., 2004). Of these, sPLA2 
hydrolyzes PLs to produce free fatty acids and a lysophospholids, whereas sSMase 
hydrolyzes sphingomyelin molecules into phosphocholines and ceramides. Indeed, 
lesional LDL shows signs of hydrolysis of both sphingomyelin and phosphatidylcholine 
(Öörni et al., 2000). In vitro studies have shown that both types of phospholipases may 
induce aggregation and fusion of LDL particles leading to increased PG binding of such 
particles (Hakala et al., 1999, Öörni et al., 2000, Hakala et al., 2001). If lipolysis of LDL 
particles is preceded by proteolysis, the PG-binding of LDL particles seems to be further 
increased (Plihtari et al., 2010). Hydrolysis of LDL by sPLA2 has also been shown to result 
in enhanced lipid accumulation in macrophages thus promoting foam cell formation 
(Hanasaki et al., 2002, Wooton-Kee et al., 2004, Lähdesmäki et al., 2012). 
In addition to phosholipolytic enzymes, other enzymes capable of hydrolyzing the lipid 
components of LDL particles within arterial intima include the lysosomal acid lipase 
(LAL) (Hakala et al., 2003) and cholesterylester hydrolase (CEH) (Torzewski et al., 1998). 
LAL is capable of hydrolyzing the CEs and TAGs of LDL and thus to generate fused 
LDL particles that are avidly taken up my macrophages (Hakala et al., 2003). CEH is an 
enzyme that hydrolyzes fatty acid esters of cholesterol and other sterols. There is evidence 
for modification of LDL by CEH in atherosclerotic lesions (Torzewski et al., 1998) 
leading to UC-rich particles that are, similar to LAL-modified LDL, efficiently taken up 
by macrophages (Torzewski et al., 2004). Moreover, LDL particles hydrolyzed by LAL or 
CEH  are able to induce proinflammatory response resulting in secretion of IL-8 from 
macrophages (Hakala et al., 2006) and ECs (Suriyaphol et al., 2002). 
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In addition to lipases, atherosclerotic lesions contain several proteases capable of 
hydrolyzing the apoB-100 of LDL in vitro. These include both plasma-derived and locally 
synthesized proteases. To the former group belong proteases plasmin, kallikrein, and 
thrombin (Piha et al., 1995) and to the latter group the matrix metalloproteinases (MMPs) 
and lysosomal proteases cathepsins D, F, K, and S secreted by intimal macrophages and 
smooth muscle cells of the lesions (Sukhova et al., 1998, Hakala et al., 2003, Öörni et al., 
2004, Plihtari et al., 2010). Additional sources of proteolytic enzymes in the arterial intima 
are the MCs (Kaartinen et al., 1994b, a). The proteolytic actions of MCs on lipoproteins 
are discussed in the later sections. 
Given that various agents capable of modifying the protein and lipid components of LDL 
are present in atherosclerotic lesions, it is not surprising that apoB-100–containing lipid 
droplets isolated from such lesions show signs of various types of modifications such as 
combined proteolysis and lipolysis (Kruth&Shekhonin 1994). Even a partial loss of apoB-
100, an important macromolecule providing for the structural integrity for LDL particle 
is likely to loosen the lipid packing on LDL surface. Loosening of the surface of LDL due 
to proteolysis can promote hydrolysis of the LDL core lipids. Indeed, the ability of CEH 
to hydrolyze CEs in LDL is facilitated by proteolytic cleavage of apoB-100 (Bhakdi et al., 
1995). Treatment of LDL with trypsin, plasmin, or MMP-2 and-9, together with CEH 
induces formation of LDL-derived lipid droplets (Chao et al., 1992, Bhakdi et al., 1995, 
Torzewski et al., 2004), showing that combined action of CEH and a protease that cannot 
alone induce LDL fusion such as plasmin (Piha et al., 1995), can trigger formation of 
LDL-derived lipid droplets in vitro. 
In addition to oxidized, lipolyzed, and proteolyzed LDL, other forms of (modified) LDL, 
such as small dense, electronegative, and especially desialylated LDL have been implicated 
in atherogenesis as well (Dousset et al., 1992, Öörni et al., 2000, Sanchez-Quesada et 
al., 2012). The following section underscores the second part of the response-to-
retention hypothesis of atherogenesis stating that the retained and modified lipoproteins 
trigger a series of events within the artery wall that ultimately leads to the formation of 
atherosclerotic lesions (Williams&Tabas 1995, Boren&Williams 2016).
1.4.4 Cellular responses to modified LDL 
The accumulated LDL particles in the arterial intima can be cleared by macrophages, 
phagocytic immune cells that have been specialized in scavenging debris from their 
surroundings. Macrophages are responsible for uptake of accumulated LDL to prevent 
cytotoxicity, tissue injury, inflammation, and metabolic disturbances. It is a well-known 
fact that modifications increase the uptake of LDL by macrophages, a phenomenon 
originally described by Drs Brown and Goldstein (Brown et al., 1979, Goldstein et al., 
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1979). The increased uptake of modified LDL is owed  to expression on macrophages 
of scavenger receptors (SRs), a group of pattern recognition receptors capable of 
recognizing and binding foreign or altered-self targets for further elimination (Canton et 
al., 2013). Modifications of LDL create recognition sites for SRs such as SR-A1 and CD36, 
which unlike the LDLR, are not subject to negative feedback regulation by intracellular 
cholesterol, allowing an unregulated accumulation of cholesterol within macrophages 
(McLaren et al., 2011, Chistiakov et al., 2017a). Over time, the macrophages become 
loaded with LDL-derived cholesterol and transform into foam cells, which are filled 
with cytoplasmic CE-containing lipid droplets (Chistiakov et al., 2017b). Although 
macrophages are the major cell type responsible for clearance of modified LDL in the 
arterial wall, the defense against the massive influx of modified LDL is partially fulfilled 
by a shift to a phagocytic phenotype of both the SMCs and endothelial cells (ECs) 
(Chaabane et al., 2014).
 
1.4.5 The stages of atherosclerotic development 
The American Heart Association (AHA) has created a detailed classification scheme 
for atherosclerotic lesions that was designed to be used as a histological “template” or 
“reference” in the clinical setting (Stary et al., 1994, Stary et al., 1995). AHA recommends 
classification of atherosclerotic lesions into 6 different numerical categories (I-VI).
1.4.5.1 Early lesions
The first isolated lipid-laden foam cells appear as a response to LDL accumulation typically 
in childhood and are considered the hallmark of the earliest stage of atherosclerotic lesion 
development, the type 1 lesion (Stary et al., 1994). Gradually, the accumulation of LDL 
sparks a local inflammatory response leading to activation of the resident arterial wall 
cells (Tabas et al., 2007). Modified LDL particles are able to activate the arterial ECs to 
express chemokines and cell adhesion molecules, such as monocyte chemotactic protein 
1 (MCP-1), intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 
1 (VCAM-1), and endothelial selectin (Cushing et al., 1990, Rajavashisth et al., 1990, Li 
et al., 1993, Leitinger et al., 1999, Zeuke et al., 2002). These molecules stimulate entry of 
inflammatory cells, mostly monocytes into the intima, where monocytes differentiate into 
macrophages and ultimately to foam cells (Rao et al., 2007, Hansson&Hermansson 2011). 
Owing to the lipid load, the foam cells lose the mobility and become unable to egress out 
of the arterial wall. Furthermore, modified LDL activates intracellular signaling networks 
in macrophages that induce production of various proinflammatory mediators such as 
chemokines, and cytokines (Stewart et al., 2010, Miller et al., 2012). Cumulatively, this has 
the effect of triggering a vicious cycle of recruiting more monocytes into the intima and of 
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opening up passages for the migration of SMCs from the media (Hansson&Hermansson 
2011). Multiple layers of macrophage foam cells and lipid-laden intimal SMCs, as well as 
scattered droplets of extracellular lipids form a thin layer of yellowish streaks, the fatty 
streak or the type II lesions (Stary et al., 1994). Furthermore, the intimal SMCs switch 
from contractile to synthetic phenotype with enhanced production of ECM components. 
Such fatty streak lesions can usually be found in the aorta in the first decade of life, in the 
coronary arteries in the second decade, and in the cerebral arteries in the third or fourth 
decades (Lusis 2000). Intermediate or type III lesions appear in young adults and contain 
lipid-laden macrophages and vascular cells. Furthermore, continued lipid accumulation 
yields pools of extracellular lipids and particles that disrupt the coherence of some intimal 
SMCs (Stary et al., 1994). Common to such early lesions is that they are focal, relatively 
small, and clinically silent. 
1.4.5.2 Advanced lesions
As stated above, subclinical atheromatous changes within the arterial wall progress silently 
for decades. During these years more complex plaques develop through continuous 
LDL accumulation and a complex series of cellular processes. The initial response to 
the subendothelial retention of LDL as an appropriate attempt to clear unwanted and 
dangerous debris from the artery wall ultimately becomes maladaptive in advanced 
atherosclerosis largely due to altered behavior of arterial phagocytes which underlies 
defects in inflammation resolution (Hansson&Hermansson 2011). Advanced lesions 
are defined as lesions that are associated with intimal disorganization. The extracellular 
lipid that can already be found as pools in type III lesions is the immediate precursor of 
the larger, confluent, and more disruptive core of extracellular lipid that characterizes 
type IV lesions also known as atheroma (Stary et al., 1995). This dense lipid core is built 
from extracellular lipids, crystallized cholesterol, and cellular debris. Failure to suppress 
continuous immune cell recruitment, to clear apoptotic cells, and to induce immune 
cell egress exacerbates plaque inflammation. As monocyte-derived macrophages, 
T lymphocytes, MCs, dendritic cells, and neutrophils accumulate the lesions, the 
inflammatory status of the plaques is heightened (Hansson&Hermansson 2011). 
Atherosclerotic lesions most often undergo a partial resolution process characterized by 
the formation of a fibrous cap consisting of ECM, mostly collagen, produced by intimal 
SMCs on top of the lipid core (Libby 2008). Fibrotic responses characterize fibroatheromas 
or type Va lesions. When the lipid core and other parts of the lesion are calcified, type V 
lesion is referred to as type Vb, whereas a type V lesion that consists mainly of fibrous 
connective tissue and little or no accumulated lipid or calcium is referred to as type Vc. 
These lesions may narrow the arteries inducing end-organ ischemia, although formation 
of a thick lesion can occur without narrowing the arterial lumen, as well. 
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Over time certain types of atherosclerotic lesions develop features that can lead to 
acute clinical complications. These so-called vulnerable or high-risk plaques contain a 
large necrotic lipid core, thin fibrous cap, and a heightened inflammatory state. Such 
vulnerable plaques are prone to surface defects such as rupture and erosion of the fibrous 
cap (Mäyränpää et al., 2006) and ensuing development of luminal thrombosis that may 
lead to a stroke or sudden cardiac death. Plaques that develop rupture, hematoma, and/or 
thrombus are classified as type VI or complicated lesions (Stary et al., 1995). 
1.5 Anti-atherogenic functions of apoA-I and HDL 
As discussed thus far, increased plasma levels of LDL-C drive atherogenesis by promoting 
lipid accumulation within the arterial wall. On the contrary, plasma levels of HDL-C 
correlate inversely with risk of atherosclerotic cardiovascular disease (ACVD) (Castelli et 
al., 1986). However, the relationship between atherosclerosis and HDL is more complex 
than that between LDL and atherosclerosis. Apparently low HDL-C is associated with 
atherosclerotic disease not in a causal way but because low HDL-C is frequently associated 
with elevated TGs (Reiner 2013, Rader 2016). Indeed, a number of pharmacological and 
genetic studies aiming to develop HDL-raising therapies have failed to demonstrate that 
increased plasma levels of HDL-C would result in reduced ACVD risk (Toth et al., 2013). 
Such studies have given rise to a controversy over whether plasma levels of HDL-C as a 
static measure of cellular cholesterol carried by plasma HDL actually reflect functional 
quality of HDL (Parhofer 2015). Indeed, there is no convincing evidence to date that 
HDL-raising agents, including CETP inhibitors, small molecules that increase apoA-I 
synthesis, or niacin reduce clinical cardiovascular events (Toth et al., 2013). The interest 
in the therapeutic potential of HDL remains high due, to a large extent, to the strength 
of the circumstantial evidence provided by pre-clinical and (limited) clinical studies 
showing that HDL can promote the regression of atherosclerosis when the levels of 
functional particles are increased exogenously or endogenously (Feig et al., 2014, Rader 
2016). Indeed, intravenous infusions of reconstituted HDL (rHDLs) particles consisting of 
complexes of PL and apoA-I as well as infusions of apoA-IMilano, a mutant form of apoA-I 
discovered in Italian families with low HDL-C but apparently decreased CV risk, have 
been shown consistently in a variety of animal models to reduce experimentally induced 
atherosclerosis (Badimon et al., 1990, Rubin et al., 1991, Chiesa et al., 2002, Nicholls et 
al., 2005, Ibanez et al., 2008). Similar antiatherogenic effect of infusing rHDLs and apoA-
IMilano into humans has been suggested by two proof-of-concept studies (Nissen et al., 
2003, Tardif et al., 2007). The disconnect between the circumstantial evidence and the 
absence of positive results in human clinical outcome trials do not eliminate HDL from 
consideration as an atheroprotective agent, but emphasizes the important distinction 
between HDL functionality and the simple static plasma levels of HDL-C. 
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To support the cardioprotective functions of HDL, numerous observations from animal 
and basic studies have shown that HDL possesses several properties that are potentially 
antiatherogenic (Mineo&Shaul 2012). The best known of these effects is the ability of HDL 
to induce cholesterol efflux from macrophage foam cells and to promote RCT (Brown et 
al., 1980, Lee-Rueckert&Kovanen 2011). Multiple pathways are known by which excess 
cholesterol in foam cells can be removed by HDL (Ji et al., 1997, Bodzioch et al., 1999, 
Wang et al., 2004). However, transport of cellular lipids to lipid-free or lipid-poor apoA-I 
by ABCA1 is the key pathway regulating macrophage cholesterol homeostasis and 
thus playing a critically important role in atherosclerosis prevention and management. 
Indeed, patients with Tangier disease have not only very low HDL levels due to mutation 
of ABCA1 (Bodzioch et al., 1999, Brooks-Wilson et al., 1999, Rust et al., 1999) but also 
suffer from excess cholesterol accumulation in tissues rich in macrophages, which 
express high levels of ABCA1 (Cavelier et al., 2001, Lawn et al., 2001, Oram&Lawn 2001). 
Subsequently, Tangier patients are at risk of premature atherosclerosis (Oram&Lawn 
2001). Further support for the essential role of ABCA1-mediated cholesterol efflux 
pathway in the context of atherosclerosis has come from numerous studies in animal 
models showing that mice overexpressing apoA-I have increased, and mice deficient in 
apoA-I have reduced, macrophage RCT (Zhang et al., 2003, Moore et al., 2005), and that 
mice deficient in ABCA1 and mice in which ABCA1 has been selectively inactivated 
have increased atherosclerosis (Aiello et al., 2002, Westerterp et al., 2013). 
Besides its classical role in regulating macrophage cholesterol homeostasis, HDL has 
plenty of other antiatherogenic properties. Indeed, HDL inhibits LDL oxidation and 
cytotoxic effects of LDL, promotes endothelial repair, improves endothelial function, has 
antithrombotic and anti-inflammatory properties, decreases white adipose tissue mass, 
increases energy expenditure, and inhibits the binding of monocytes to the endothelium 
(Cockerill et al., 1995, Morgantini et al., 2011, Mineo&Shaul 2012, Gordts et al., 2014). 
Many of the atheroprotective functions of HDL are attributed to apoA-I and are mediated 
by apoA-I interaction with ABCA1 (Mineo&Shaul 2013, Vuilleumier et al., 2013).
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2 Mast cells
MCs are tissue-dwelling cells of hematopoietic origin currently emerging as 
multifunctional effector cells in numerous settings. MCs have become widely known 
for their detrimental actions in diseases such as allergic asthma, contact dermatitis, 
rheumatoid arthritis, atherosclerosis, and cancer (Eklund 2007, Balzar et al., 2011, 
Dudeck et al., 2011, Bot et al., 2015, Rao et al., 2015), whereas less well advertised is the 
beneficial action of MCs, most notably in the context of host defense toward insults by 
bacteria, parasites, and various toxic substances (Echtenacher et al., 1996, Malaviya et 
al., 1996, Maurer et al., 2004, Schneider et al., 2007, Akahoshi et al., 2011, Matsuguchi 
2012, Cruz et al., 2014). The capability of MCs to participate in various processes, both 
of detrimental and beneficial nature, is attributed to a wide variety of inflammatory 
molecules such as histamine, heparin proteoglycan (PG), cytokines, chemokines, lipid-
derived mediators, and various neutral proteases released by MCs upon activation. Many 
of these mediators, most notably histamine, heparin, and neutral proteases, are stored 
within abundant cytoplasmic secretory granules of MCs, specific intracellular organelles, 
whose characteristic staining property (Figure 4), termed metachromasia, initially led to 
the identification of these effector cells in the late 19th century (Wernersson&Pejler 2014). 
Since the discovery of MCs, it has become obvious that MCs do not represent a 
homogeneous population of cells but display marked plasticity in their morphological, 
histochemical, biochemical, and functional characteristics depending on their anatomic 
localization (Metcalfe et al., 1997). In humans, the most precise marker of MC 
heterogeneity is the neutral granule protease content. Two major MC subtypes within 
human tissues distinguishable by their protease phenotype have been established (Irani et 
al., 1986, Irani et al., 1989), however, increasing evidence now suggests that the phenotypic 
heterogeneity of human MCs may actually be more complex (Weidner&Austen 1993, 
Andersson et al., 2009, Abonia et al., 2010, Dougherty et al., 2010, Andersson et al., 2011, 
Andersson et al., 2018).
Figure 4. Human MC displaying metachromatic staining. Human MCs were cultured for 9 weeks and stained with 
toluidine blue, which turns the cytoplasmic secretory granules of MCs from a blue to a reddish color due to interaction 
of the basic dye with the highly sulfated glycosaminoglycans, notably heparin, within MC secretory granules. Image 
from (Lappalainen et al., 2007).
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2.1 Mast cell origin and differentiation
MCs derive from hematopoietic stem cells in the bone marrow. However, MCs are rather 
unique among cells of hematopoietic origin in that they undergo only part of their 
differentiation in the bone marrow, with the bulk differentiation occurring in peripheral 
tissues under the influence of the local microenvironment (Okayama&Kawakami 2006). 
The bone marrow origin of MCs was first demonstrated through a series of in vivo 
reconstitution studies using genetically MC-deficient mutant mice (Kitamura et al., 1978, 
Kitamura et al., 1981). In the early 1990s, the origin of human MCs from pluripotent 
CD34+ progenitor cells in the bone marrow was demonstrated (Kirshenbaum et al., 1991). 
However, MCs do not complete their differentiation in the bone marrow, but leave the 
bone marrow as immature precursors and circulate in the blood as agranular leukocytes 
(Dahlin&Hallgren 2015). In vitro human MCs can be differentiated from peripheral 
blood-derived progenitors expressing a CD34 and a receptor tyrosine kinase for stem cell 
factor/kit ligand (SCF/KITLG) designated as KIT (Agis et al., 1993, Kirshenbaum et al., 
1999). Recently a human tissue MC–like cells were developed in vitro from a population 
of peripheral blood-derived Lin(-) CD34(hi) CD117(int/hi) FcεRI(+) cells, suggesting 
that this rare population of precursor cells may represent circulating progenitors that give 
rise exclusively to MCs (Dahlin et al., 2016).
From the circulation, the MC progenitors are recruited into various peripheral tissues, 
where they complete their differentiation into mature MCs. From murine studies, it 
has become apparent that MC homing is a precisely controlled process, where integrin 
adhesion molecules play an important role (Hallgren&Gurish 2011, Dahlin&Hallgren 
2015). Human MC progenitors have been reported to use α4β1-integrin for adhesive 
interactions with human vascular endothelium (Boyce et al., 2002). Furthermore, human 
MC progenitors express several chemokine receptors, CXCR2, CCR3, CXCR4, and CCR5, 
and respond in vitro to their ligands IL-8, eotaxin, stromal cell-derived factor (SDF)-1α, 
and macrophage inflammatory protein (MIP)-1α, respectively (Ochi et al., 1999). 
The details of human MC differentiation within tissues have not been fully covered, 
however it is known that human MCs undergo optimal development in the presence 
of KITLG (Irani et al., 1992b, Valent et al., 1992, Mitsui et al., 1993). Stimulation of 
MCs by KITLG promotes differentiation, proliferation, maturation, and survival of 
MCs and their progenitors (Okayama&Kawakami 2006), while deprivation of KITLG 
results in rapid apoptosis of MCs both in vivo and in vitro (Iemura et al., 1994). KITLG 
elicits its functions through KIT, which is expressed on the surface of MCs throughout 
their development, unlike in other cells of hematopoietic origin that express KIT only 
during their early stages of development (Miettinen&Lasota 2005). The importance of 
KIT signaling in MC development is stressed by the 4 following facts: first, mice with 
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defects in KITLG (Sl/Sld mutants) or KIT (W/Wv mutants) are strikingly deficient in 
mature tissue MCs (Kitamura et al., 1978, Kitamura&Go 1979); second,  in all variants 
of mastocytosis characterized by uncontrolled MC proliferation activating mutations 
of KIT are found (Bibi et al., 2014); and third, injection of KITLG into experimental 
animals (Galli et al., 1993) and human subjects results in MC hyperplasia (Costa et al., 
1996). Consistent with this latter finding, subcutaneous administration of recombinant 
rat KITLG locally repaired the MC-deficiency in Sl/Sld mutant mice (Zsebo et al., 1990). 
2.2 Mast cells are multifunctional effector cells
Mast cells are widely distributed throughout body and can be found in virtually all 
vascularized tissues especially at sites close to or in contact with the outside world, for 
example in the skin and the mucosal surfaces of the respiratory and gastrointestinal tracts 
(Galli et al., 2005). The localization of MCs at sites close to the external milieu reflects 
their role as being among the first cells of immune system to interact with environmental 
antigens and allergens, invading pathogens or environmental toxins (Metz&Maurer 
2007). MCs are best known for their prominent role in IgE-associated hypersensitivity 
reactions and allergic disorders, however, it has become obvious that MCs can contribute 
to many processes of both innate and adaptive immunity and can exert both protective 
and pathogenic functions (Metz&Maurer 2007, Galli et al., 2008). Such effector 
functions include killing pathogens, degrading potentially toxic endogenous peptides or 
components of venoms, and regulating the numbers, viability, distribution, phenotype 
or non-immune functions of structural cells, such as fibroblasts and vascular endothelial 
cells (Metz et al., 2006, Dawicki&Marshall 2007, Kovanen 2007a, Galli et al., 2008). 
MCs mediate their effector functions by releasing upon activation a wide range of preformed 
and de novo-synthesized mediators such as histamine, heparin, neutral proteases, 
arachidonic acid-derived lipid mediators, numerous cytokines, chemokines, and growth 
factors (Theoharides&Cochrane 2004, Grimbaldeston et al., 2006, Metz&Maurer 2007) 
(Table 2). MCs can also have positive, as well as negative immunomodulatory roles in vivo. 
These roles reflect the ability of MCs to influence recruitment, survival, development, 
phenotype or function of immune cells, including granulocytes, monocytes/macrophages, 
dendritic cells, T cells, B cells and  natural killer cells (Galli et al., 2008). Through these 
effector and immunomodulatory functions, which can either promote or suppress certain 
features of an immune response, depending on the individual biological setting, MCs can 
contribute to numerous physiological and pathophysiological conditions such as host 
defense, innate and adaptive immune responses, homeostatic responses, angiogenesis, 
wound healing, tissue remodeling, and immunoregulation (Dawicki&Marshall 2007, 
Metz&Maurer 2007, Galli et al., 2008, Rao&Brown 2008, Maltby et al., 2009). Crucial 
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functions for MCs in a variety of disorders such as rheumatic arthrititis (Eklund 
2007), multiple sclerosis (Theoharides et al., 2007a), fibrosis (Holdsworth&Summers 
2008), tumor growth (Maltby et al., 2009), inflammatory bowel disease (He 2004), and 
cardiovascular diseases, such as atherosclerosis (Kovanen 2007a), has been established 
ensuring that MCs are currently receiving increased attention among the scientific field 
outside of the allergy-related programs of research.
2.2.1 Mast cells release a wide variety of inflammatory mediators upon activation
MCs are equipped with an arsenal of cell surface receptors, through which they can be 
stimulated to release the wide array of biologically active compounds. The receptors 
include those for immunoglobulin (Ig) A (FcαR), IgE (FcεRI), and IgG (FcγRI, FcγRIIA, 
FcγRIIB, FcγRIII), receptors for C3α (C3α receptor) and C5α (C5α receptor), Mrgprb2/ 
receptor (a receptor for basic secretagogues) and its human ortholoque MRGPRX2 
(McNeil et al., 2015), and toll like receptors (TLRs) 1-9 (Theoharides et al., 2012). The 
classical mechanism of MC activation is crosslinking via an IgE-specific antigen or 
allergen of IgE bound to its high affinity receptor, FcεRI, on the surface of MC (Galli&Tsai 
2012). Crosslinking activates the FcεRI signaling pathway leading to acute release of 
preformed mediators, such as histamine, heparin, and neutral proteases stored within 
the cytoplasmic secretory granules, in an exocytotic process called degranulation. In 
addition to allergic triggers, MCs can be activated by numerous other immunological 
and non-immunological signals such as anaphylatoxins, antibody light chains, bacterial 
and viral antigens, various cytokines and chemokines, neuropeptides, chemical agents, 
and physical stimuli (Metz&Maurer 2007, Theoharides et al., 2007b). At later stages upon 
activation, MCs can also release newly synthesized mediators such as various cytokines, 
chemokines, arachidonic acid-derived lipid mediators, and growth factors. Depending on 
the mechanism of activation and the strength of the activating stimulus, MCs may release 
mediators belonging to either category (preformed mediators and newly synthesized 
mediators) or they may secrete distinct subsets of mediators through selective release 
without degranulation. Example of the former is IgE-mediated degranulation, whereas 
the latter may happe for example upon binding of lipopolysaccharide (LPS) to TLR-4 
expressed on the MC surface (Theoharides et al., 2007b). 
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2.3 Mast cell neutral proteases 
The major group of preformed mediators based on abundance is the neutral proteases, 
proteolytic enzymes having a neutral-to-slightly-basic pH optimum, which can account 
for up to 35% of the total cellular protein (Hellman and Thorpe, 2014). The neutral 
proteases are stored in high amounts as proteolytically active enzymes within the 
MC cytoplasmic granules (Pejler et al., 2007) embedded  in a matrix of heparin PGs 
(Kovanen, 1993). Although stored in their fully active form, the acidic pH inside the 
granules restricts their activity during storage (Wernersson and Pejler, 2014). Once 
MCs are triggered to degranulate they expel some of their granules into the extracellular 
spaces, where proteases remain bound to heparin forming proteolytically active granule 
remnant s ready to act on their targets (Figure 5).
Figure 5. Scanning electron micrographs of a resting and a degranulating rat serosal MC. Under normal 
conditions, MCs are found in tissues in their resting state storing the various neutral proteases, histamine, and 
various preformed mediators in their cytoplasmic granules (Left panel). However, upon activation with an 
appropriate stimulus, such as crosslinking of receptor-bound IgE by an antigen, MCs acutely exocytose their 
preformed mediators in a process called degranulation (Right panel). In the extracellular fluid, histamine and 
other soluble mediators detach from heparin and diffuse away, whereas a fraction of the exocytosed neutral 
proteases remain bound to the granule heparin proteoglycan matrix, thereby forming a proteolytically active 
granule remnant (Kokkonen&Kovanen 1990).
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Table 2. Mast cell granule-associated mediators
Biogenic amines Enzymes Proteoglycans
Dopamine Arylsulfatases Serglycin
Histamine Carboxypeptidase A3 Glycosaminoglycans
Serotonin Cathepsin G Heparin
Growth factors and Cytokines Chymase Chondroitin sulfate
IL-1, IL-3, IL-4, IL-5, IL-6, TNF-α, β-Glucuronidase Chemokines
IL-10, IL-13, GM-CSF, KITLG, TGF-β Granzyme B MIP-1α, MIP-1β
Granzyme H IL-8, RANTES, MCP-1, eotaxin
Kinogenases Lipid-derived mediators
MMP-9 Leukotriene B4
Phospholipases Leukotriene C4
Peroxidases Platelet activating factor
Tryptase Prostaglandin D2
GM-CSF, granulocyte-macrophage colony-stimulating factor; MCP-1, monocyte chemotactic protein-1; 
MIP:, macrophage inflammatory protein, MMP-9, matrix metalloproteinase-9; RANTES, regulated upon 
activation normal T cell expressed and secreted; TNF-α, tumor necrosis factor-α; KITLG, kit ligand; Data 
from (Shakoory et al., 2004, Rönnberg et al., 2014, Wernersson&Pejler 2014). 
Neutral protease activity was first demonstrated in MCs (of human, dog, rat, mouse, 
rabbit) in the early 1950s by the use of histochemical technique involving cleavage of 
a chromogenic substrate [reviwed in (Nakamura et al., 2009)]. Further studies in the 
late 1950s characterized this activity as a chymotrypsin-like enzyme on the basis of its 
preference of hydrolyzing acetylethyl esters of aromatic amino acids, but of not basic 
amino acids (Benditt&Arase 1959). A year later, using other substrate-based techniques 
(Glenner&Cohen 1960), human skin MCs were reported to contain substantial levels of 
trypsin-like enzyme activity.  However, it took over 20 years until tryptase and chymase 
responsible for trypsin-like and chymotrypsin-like enzyme activities, respectively, were 
first isolated and characterized (Schwartz et al., 1981, Schechter et al., 1983). Nowadays 
various neutral proteases, namely chymase, carboxypeptidase A3 (CPA3), cathepsin G, 
granzyme B, and tryptases of four isoforms have been identified within the granules of 
human MCs (Caughey 2016). Furthermore, a novel protease, granzyme H was reported 
in 2014 to be present within human MCs (Rönnberg et al., 2014). Apart from CPA3, 
which is a zinc-containing exopeptidase of the metalloproteinase family (Pejler et al., 
2009), all MC neutral proteases are serine proteases characterized by an active site serine 
residue.
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2.3.1 Tryptase
Tryptase is present in most, if not all, human MCs, and is the major neutral protease 
stored in human MC granules in terms of abundance (Metcalfe et al., 1997). Tryptase has 
trypsin-like cleavage specificity, as it cleaves protein substrates at the C-terminal side of 
arginine and lysine residues (Schwartz et al., 1981, Tanaka et al., 1983). However, unlike the 
many tryptic peptidases associated with digestion, hemostasis, clot lysis, and complement 
activation, tryptase is highly selective regarding its peptide and protein targets (Schwartz 
et al., 1981, Tanaka et al., 1983), which underscores its unique position in the hierarchy 
of peptidases belonging to the trypsin family. The human MC tryptase locus resides on 
chromosome 16p13.3 and spans approximately 1.6 Mb (Pallaoro et al., 1999). To date, 
four MC tryptase genes (TPSAB1, TPSB2, TPSD1, and TPSG1) plus various pseudogenes 
have been identified in humans (Pallaoro et al., 1999, Caughey et al., 2000). These fall 
into two major groups: the soluble α-, β-, and δ-tryptases and the membrane-anchored 
γ-tryptase, also known as transmembrane tryptase or TMT (Pallaoro et al., 1999). Of 
these, the β-tryptase appears to be the main form stored in human MC granules, and it 
occurs in three almost identical forms: βI, βII, and βIII (Miller et al., 1990, Vanderslice et 
al., 1990). MC tryptase has several unique features, one of the most remarkable ones being 
its organization into a tetrameric state with the active sites oriented toward a narrow central 
pore, and its consequent resistance to endogenous macromolecular protease inhibitors, 
such as serpins and α2-macroglobulin (Pereira et al., 1998). 
Among the α-tryptases, two very similar forms have been identified in humans: αI and 
αII (Miller et al., 1989, Pallaoro et al., 1999). In contrast to β-tryptase, which is stored 
in the secretory granules and not released unless the MCs have been challenged by a 
degranulating stimulus, α-tryptase appears to be constitutively released via a selective 
pathway and is present at low levels in circulation even without MC degranulation 
(Schwartz et al., 1995). However, the activity of human α-tryptase is extremely low 
compared with β-tryptase, which is partly due to the amino acid substitution of glycine 
for asparagine at the position 216 of the substrate-binding pocket (Huang et al., 1999). 
In some individuals elevated basal serum tryptase levels are found due to increased copy 
number of α-tryptase (Lyons et al., 2016)
From δ-tryptase, two nearly identical forms (δI and δII) have been identified (Wang et 
al., 2002). However, the activity of δ-tryptase is also much lower than that of β-tryptase, 
which is mainly due to a premature stop codon that results in a truncated protein and 
affects the substrate specificity of δ-tryptase significantly (Wang et al., 2002).
Finally, two different forms of the human transmembrane tryptase (γ-tryptase) have 
been identified: γI and γII (Caughey et al., 2000). The γ-tryptases contain an extended 
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hydrophobic C-terminal domain followed by a small cytoplasmic tail, are anchored in 
either the plasma membrane or the secretory granule membrane, and only act locally 
upon MC activation (Caughey et al., 2000).
2.3.2 Chymase
In humans, the major chymotryptic protease, as defined by its preference for cleaving 
peptide and protein substrates at the C-terminal site of aromatic amino acids, such as 
phenylalanine, tyrosine, and tryptophan, is chymase (Powers et al., 1985, Caughey 2007). 
In contrast to rodents, which express several chymase isoforms (Pejler et al., 2007), only 
one chymase gene (CMA1) has been found in humans (Caughey et al., 1993). Chymase 
is specifically expressed in MCs (Caughey 2016). Human MC chymase is located on 
chromosome 14q11.2 (Caughey et al., 1993) at the end of a small cluster of four genes 
covering approximately 130 kb. This cluster also contains the cathepsin G gene (CTSG) 
and the granzyme H and B genes (GZMH and GZMB, respectively) (Caughey et al., 1993). 
The human chymase is active in its monomeric form (Pejler et al., 2007) and has more 
destructive potential than tryptase, given that it can cleave a fairly wide variety of peptide 
and protein targets (Caughey 2007). Befitting its greater destructive potential, chymase is 
more susceptible to inhibition by circulating and extravascular anti-peptidases, including 
serpins and α2-macroglobulin, and is thus quickly inhibited after release, although some 
protection against inhibition is gained by tight binding to co-released PGs, notably the 
heparin PGs (Pejler&Berg 1995, Lindstedt et al., 2001, Caughey 2007). Chymase is closely 
associated with cardiovascular disorders (Kovanen 1997).  It is activated in pressure-
overloaded hearts and is able to convert angiotensin I to angiotensin II independently of 
the angiotensin-converting enzyme (Doggrell&Wanstall 2005). 
2.3.3 Carboxypeptidase A3
Human CPA3 is a zinc-dependent metalloexoprotease that belongs to the carboxypeptidase 
(CP) A/B family (Arolas et al., 2007). As indicated by the letter "A" in its name, CPA3 has a 
CPA-like cleavage specificity, i.e., it prefers cleaving peptide and ester bonds at the amino side 
of the C-terminal aromatic amino acids (Goldstein et al., 1989). Human CPA3 is encoded 
by a single gene (CPA3), which situates on chromosome 3q24 (indicated by number 3 in 
its name) and spans over 32 kb (Pejler et al., 2007). It has been identified in the MCTC and 
in MCs containing tryptase and CPA3 but not chymase (Goldstein et al., 1989, Abonia et 
al., 2010, Dougherty et al., 2010). Despite having a CPA-like substrate-binding pocket and 
enzyme activity, CPA3 is structurally similar to bovine and human pancreatic CPB, which 
indicates its uniqueness among CPs (Goldstein et al., 1989, Reynolds et al., 1992).
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2.3.4 Cathepsin G
Human cathepsin G is a serine protease that belongs to the cathepsin class of enzymes 
(Kryczka&Boncela 2017). Unlike tryptase, chymase, and CPA3, which are considered MC-
specific proteases, expression of cathepsin G is traditionally related to neutrophils (Korkmaz 
et al., 2008). However, studies have provided evidence that also other cells, such as monocytes 
and macrophages, do express cathepsin G (Wang et al., 2014). Only one cathepsin G gene 
(CTSG) has been identified in humans, and it is located within a cluster of four genes 
on chromosome 14q11.2 (Caughey et al., 1993). Similar to chymase, cathepsin G has 
chymotrypsin-like activity, but, in terms of its destructive potential, cathepsin G is a weaker 
enzyme than chymase, and it also has a broader peptidase specificity; that is, it exhibits the 
unusual property of having both chymotryptic and tryptic activity (Caughey 2007).
2.3.5 Granzyme B
Granzymes are serine proteases classically known as granule components of cytotoxic 
T lymphocytes and natural killer cells (Lieberman 2003). After being released by these 
cells granzymes induce apoptosis in target cells, thus eliminating cells that have become 
cancerous or have been infected with bacteria and viruses (Bots&Medema 2006). Five 
granzyme subtypes have been identified in humans (A, B, H, K, and M) (Barry&Bleackley 
2002), granzyme B being the most thoroughly characterized of them (Ngan et al., 2009). 
Granzyme B was first identified within human MCs in 2007 (Strik et al., 2007). It has been 
reported to be present in cultured human MCs and in MCs of human skin (Strik et al., 
2007; Rönnberg et al., 2014). Granzyme B is a caspase-like serine protease that cleaves 
substrates at the carboxyl side of acidic residues, particularly aspartic acid (Fan&Zhang 
2005). The granzyme B of lymphocytes and NK cells is a pro-apoptotic protease, which 
requires perforin to form pores in the plasma membrane of the target cells to help its 
entry into intracellular compartments (Fan&Zhang 2005). Unlike lymphocytes, MCs do 
not store perforin in their secretory granules (Pardo et al., 2007), which suggests a unique 
function of MC-derived granzyme B. Human MC-derived granzyme B is released from 
MC secretory granules upon activation (Strik et al., 2007). Extracellular granzyme B is 
able to cleave a number of ECM proteins (Hellman&Thorpe 2014), yet the understanding 
of the extracellular effects of human MC granyme B is limited. Recently it was, however, 
reported that by secreting matrix-degrading granzyme B MCs may alter the proliferative 
and organizational state of endothelial cells leading to reduced efficacy of anti-angiogenic 
therapy (Wroblewski et al., 2017).  
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2.3.6 Granzyme H
Another granzyme, namely granzyme H, which is constitutively expressed at high levels 
in human natural killer cells was recently identified in cultured human MCs and MCs 
of human skin (Rönnberg et al., 2014). As a member of a granzyme family, granzyme H 
is a death-inducing protease. On the contrary to granzyme B, granzyme H appears to be 
able to induce caspase-independent cell death (Fellows et al., 2007),  although induction 
of caspase-dependent apoptosis of target cells by granzyme H has also been reported 
(Hou et al., 2008). In human MCs granzyme H and B seem to be reciprocally regulated 
(Rönnberg et al., 2014)supporting earlier findings obtained in T lymphocytes and natural 
killer cells (Sedelies et al., 2004)
2.4 Mast cell heterogeneity
Human MCs have traditionally been classified into two major subsets, the MCT, which 
contains only tryptase and the MCTC, which contains both tryptase and chymase (Irani et 
al., 1986) as well as carboxypeptidase A3 (CPA3) and cathepsin G (Schechter et al., 1990, 
Irani et al., 1991). This classification is based on the classical studies of Schwartz and 
his group (Irani et al., 1986, Irani et al., 1989) using newly developed antibodies against 
tryptase and chymase, that had, as mentioned, been isolated and characterized a couple of 
years earlier. Since the studies of Schwartz and coworkers, the concept of the existence of 
two MC subtypes, the MCT and the MCTC have held tight, although two ‘additional’ MC 
phenotypes namely MCC designating a MC containing chymase only (Weidner&Austen 
1993), and a MC containing tryptase and CPA3 but not chymase have been identified 
within human tissues (Weidner&Austen 1993, Abonia et al., 2010, Dougherty et al., 
2010). However, many researchers have failed to detect the MCC phenotype within 
human tissues (Irani et al., 1989, Tetlow&Woolley 1995, Gotis-Graham&McNeil 1997) 
providing a plausible explanation why its existence has often been neglected. An MC 
containing tryptase and CPA3, again, has been relatively recently (in 2010) identified 
(Abonia et al., 2010, Dougherty et al., 2010) but has not, at least yet, gained an established 
status as a major human MC phenotype.
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Table 3. Distribution of MCT, MCTC, and MCC in normal human tissues
Tissue % MCT % MCTC % MCC
Skin <1 >99
Lung
Alveoli 91/93 8/7 1/-
Bronchi 78 10 12
Bronchial epithelium 100 0 -
Bronchial subepithelium 75 25 -
Axillary lymph nodes 1 97 2
Breast parenchyma 1 99 0
Stomach
Mucosa 52 39 9
Submucosa 0 73 27
Small intestine
Mucosa 65/81 31/19 4/-
Submucosa 0/23 76/77 24/-
Colon
Mucosa 53 37 10
Submucosa 0 96 4
Nasal mucosa 66 34 -
Conjunctiva 5 95 -
Synovium 17/34 83/66 -/-
Heart 10 90 -
Kidney 65 35 -
Uterus
Endometrium 84 16 -
Inner myometrium 48 52 -
Outer myometrium 10 90 -
Cervix 40 60 -
Data from (Weidner&Austen 1993, Irani&Schwartz 1994, Sperr et al., 1994, Mori et al., 1997, Buckley et al., 
1998, Gotis-Graham et al., 1998, Yamada et al., 2001). Data are expressed as mean. -, Data not available; /, 
different values given by the authors.
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2.4.1 Tissue distribution of human mast cell subtypes
Intially, the human MCT and MCTC subtypes were suggested to be the equivalents of the 
previously described ‘mucosal’ and ‘connective’ tissue MCs of rodents, respectively, but 
their  tissue distribution is not as clearly demarcated as that in rodents. Different groups 
of investigators have reported quite different proportions of MCT and MCTC subtypes in 
various human tissues. However, some rules appear to govern the tissue distribution of 
MCT and MCTC subtypes. In histologically normal human tissues, MCT is the primary 
subtype at the mucosal surfaces of the respiratory and gastrointestinal tracts, such as 
in the lungs, particularly the alveoli, and the small intestinal mucosa, whereas MCTC is 
the predominant subtype found in the skin, synovium, and gastrointestinal submucosa 
(Table 3). Although a particular MC subtype seems to predominate in a particular tissue, 
a fraction of the other subtype is also usually present. Indeed, most human tissues contain 
a mixed population of MCT and MCTC subtypes, their relative abundances changing 
with inflammation and other disease processes (Table 4). 
Table 4. Relative abundances of MCT and MCTC in normal and diseased human tissues
MC
subtype
Synovium Kidney Carotid Artery
Normal Early 
RA
Late
RA
Normal Rejected
nephrect. 
specimens
Rejected
biopsy 
specimens
Normal Early
lesion
Advanced 
lesion
MCT 17% 72% 37% 65% 65% 71% 10-20% 30-40% 0-10%
MCTC 83% 28% 63% 35% 35% 29% 80-90% 60-70% 90-100%
RA; Rheumatoid arthritis; Data from (Jeziorska et al., 1997, Gotis-Graham et al., 1998, Yamada et al., 2001)
47
2.4.2 The relationship between mast cell differentiation and protease phenotype
The details of human MC differentiation and phenotypic diversification in local tissue 
microenvironment are not well understood. The concept about the developmental 
relationship between MCTC and MCT has been particularly controversial; whether 
these phenotypes represent committed subtypes deriving from two distinct circulating 
progenitors with irreversibly predetermined protease phenotypes, or whether they derive 
from a common circulating progenitor cell and represent functional states that MCs 
assume under the influence of the local microenvironment (Figure 6).
Figure 6. Two models for human MC development. MCs derive from pluripotent hematopoietic CD34+ 
progenitor cells in the bone marrow, leave the bone marrow at their immature state and circulate as agranular 
CD34+/KIT+ progenitor cells. From the circulation, the MC progenitors migrate into various peripheral 
tissues, where they undergo terminal differentiation under the influence of local growth factors and cytokines, 
most importantly KITLG. Two models for the development of MCT and MCTC have been suggested. First, 
MCT and MCTC derive from two distinct progenitors with irreversibly predetermined protease phenotypes, 
and no transdifferentiation between the two MC subtypes exists (Left panel). Second, MCT and MCTC 
derive from a common progenitor cell, and microenvironmental factors, such as cytokine milieu, ultimately 
determine the protease phenotype. Thus, MCT and MCTC can switch phenotypes alongwith changes in the 
local microenvironment, a phenomenon referred to as phenotypic plasticity (Right panel). Adapted from 
(Nigrovic&Lee 2013).
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X
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The establishment of culture systems for human MCs has provided a powerful tool for 
the investigation of MC development. Several factors are now known to be capable of 
regulating the KITLG-dependent MC development (Table 5). In human cell culture 
systems, T cell-derived cytokines, such as interleukin (IL)-3, IL-4, IL-6, and IL-9, promote 
proliferation and maturation of MCs (Kirshenbaum et al., 1992, Kinoshita et al., 1999, 
Matsuzawa et al., 2003, Lappalainen et al., 2007) and may skew the MC phenotype towards 
either the MCT or MCTC (Toru et al., 1998, Kinoshita et al., 1999). Indeed, in vitro systems 
have helped to demonstrate that MC protease phenotype may be directed at least to some 
extent by certain cytokine patterns that are present in the local microenvironment (Toru 
et al., 1998, Kinoshita et al., 1999, Ahn et al., 2000). Although several studies using in vitro 
generated human MCs (Saito et al., 1996, Toru et al., 1998, Kinoshita et al., 1999, Shimizu 
et al., 2002, Wong&Stevens 2005, Yasuda et al., 2005) have provided important insights 
about the relationship between MC development and protease expression, differences in 
the source of progenitor cells, culture conditions, analysis period, and methods used to 
detect the proteases have made it difficult to establish a clear concept of the developmental 
pathway(s) leading to the different MC subtypes. 
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Table 5. Growth factors and cytokines that regulate human MC development, proliferation, and survival
Growth factor/Cytokine Function 
IFN-γ • Inhibits MC growth and differentiation (Kirshenbaum et al., 1998)
• Inhibits early progenitor cell division (Kulka&Metcalfe 2005) 
• Promotes survival of cultured human MCs (Yanagida et al., 1996)
IL-3 • Promotes development of MCs synergistically with KITLG 
  (Kirshenbaum et al., 1992) 
• Promotes growth of mature MCs (Gebhardt et al., 2002) 
• Does not affect the differentiation of human MCs (Shimizu et al., 2008)
IL-4 • Promotes MC maturation accompanied with increased frequency of MCTC  
   phenotype (Toru et al., 1998, Ahn et al., 2000)  
• Upregulates FcεRI expression 
   (Toru et al., 1996, Xia et al., 1997, Iida et al., 2001) 
• Increases mediator release (Iida et al., 2001) 
• Inhibits MC growth during early stage of development (Nilsson et al., 1994b) 
• Induces apoptosis of MC progenitors (Oskeritzian et al., 1999)
• Inhibits early KIT expression (Nilsson et al., 1994b, Kulka&Metcalfe 2005)  
IL-6 • Promotes MC maturation accompanied with increased frequency of MCTC 
   phenotype (Kinoshita et al., 1999, Moon et al., 2003) 
• Increases histamine content (Kinoshita et al., 1999)
• Reduces/inhibits apoptosis (Kambe et al., 2001)
IL-9 • Increases proliferation of MC progenitors synergistically with KITLG during 
   early stage of MC development (Matsuzawa et al., 2003, Lappalainen et al., 2007)
• Does not affect human MC differentiation (Lappalainen et al., 2007)
IL-33 • Enhances the survival of naïve human MCs and promotes their adhesion to 
   fibronectin (Iikura et al., 2007)
• Induce cytokine production in human mast cells even in the absence of 
  stimuli of FcεRI aggregation (Iikura et al., 2007)
KITLG • Promotes proliferation, differentiation, survival, and cell–cell and 
   cell–substratum adhesion (Okayama&Kawakami 2006)
• Stimulates selective growth of human MCs from hematopoietic progenitors  
   (Irani et al., 1992b, Valent et al., 1992, Mitsui et al., 1993, Kinoshita et al., 
   1999, Maaninka et al., 2013)
• Induces expression of various human MC neutral proteases 
   (Maaninka et al., 2013)
• Induces production of tryptase and histamine (Valent et al., 1992)
• Induces chemotaxis (Nilsson et al., 1994a) 
• Activates mediator release (Columbo et al., 1992, Sperr et al., 1993) 
• Enhances degranulation and cytokine production through crosslinking of 
   FcεRI (Hundley et al., 2004)
NGF • Promotes development of cord blood-derived human MCs (Welker et al., 2000)
• Promotes MC maturation by up-regulating tryptase, FcεRI, and histamine   
   (Welker et al., 1998)
• Prevents apoptosis of cord blood-derived human MCs synergistically with  
   KITLG (Kanbe et al., 2000)
Neurotrophin-3 • Promotes maturation of human intestinal MCs (Lorentz et al., 2007) 
TGF-β • Inhibits MC development (Kinoshita et al., 1999, Hjertson et al., 2003, 
   Ishida et al., 2003)
IFN-γ, interferon-γ; NGF, nerve growth factor; TGF-β, transforming growth factor-β
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2.5 Mast cells and atherosclerosis 
Histopathological studies of atherosclerotic lesions have emphasized the presence 
of increased numbers of MCs in the atherosclerotic arteries compared to the level in 
normal healthy arteries (Atkinson et al., 1994, Kaartinen et al., 1994b, Jeziorska et al., 
1997). In normal human coronary arterial intima only few MCs (on average 1 MC/mm2, 
0.1% of total intimal cells) are present while in fatty streaks fivefold higher values (on 
average 5 MCs/mm2, 0.9% of total intimal cells) have been reported (Kaartinen et al., 
1994b). The number of MCs in the cap and core regions of atherosclerotic plaques in 
the coronary arteries is on average 2 MCs/mm2 (0.5% of total intimal cells), while the 
shoulder regions of the plaques contain on average 6 MCs/mm2 (1.1 % of total intimal 
cells) (Kaartinen et al., 1994b). The actual sites of plaque erosion and rupture are highly 
infiltrated with MCs (28 MCs/mm2, 6% of total intimal cells) suggesting a role for MCs in 
these atherothrombotic events (Kovanen et al., 1995). In the human aorta, even normal 
intima contains substantial numbers of MCs (15 MCs/mm2) and the numbers do not 
increase in fatty streaks (15 MCs/mm2) or atheromas (3 MCs/mm2) (Kaartinen et al., 
1994a). Thus, the number of MCs in the intima of coronary and carotid arteries, but not 
of aorta, increases as the atherosclerotic plaques become more advanced (Kaartinen et al., 
1994a, b, Kovanen et al., 1995, Jeziorska et al., 1997). The medial layer of both normal and 
atherosclerotic arteries are mainly devoid of MCs (Kaartinen et al., 1994a, Jeziorska et al., 
1997), although occasional medial MCs have been reported in atherosclerotic arteries 
(Atkinson et al., 1994). In the outermost layer of the vessel wall, the adventitia, high 
numbers of MCs are seen even in normal coronary arteries (19 MCs/mm2), and their 
numbers are increased in atherosclerotic arteries both in non-ruptured plaques (41 MCs/
mm2) and in ruptured plaques (98 MCs/mm2) (Laine et al., 1999). The accumulation of 
MCs in the arteries is considered to be mediated by KITLG expressed in the arterial ECs 
and SMCs (Miyamoto et al., 1997), and by eotaxin expressed in activated vascular SMCs 
(Haley et al., 2000).
In the aortic and coronary intima, all MCs contain tryptase, and a proportion of MCs 
also contain chymase (Kaartinen et al., 1994a). The percentage of chymase-containing 
MCs however, whether in aorta or coronary of healthy or atherosclerotic intima, shows 
high interindividual variation (Kaartinen et al., 1994b, a, Kovanen et al., 1995). MCs 
containing cathepsin G have also been detected in atherosclerotic arteries (Mäyränpää et 
al., 2006). Indeed, a recent immunohistochemical study analyzing the occurrence of MCs 
in atherosclerotic plaques showed significantly higher numbers of tryptase+, chymase+, 
and cathepsin G+ MCs in atherosclerotic lesions compared to healthy vessels (Rohm et 
al., 2016). The various MC phenotypes are likely to provide different functional properties 
following activation/degranulation in vivo.
51
Indeed, activation/degranulation of MCs is a common feature in the atherosclerotic 
plaques (Kaartinen et al., 1994b, Kovanen et al., 1995, Jeziorska et al., 1997). In human 
coronary atheromas, the number of degranulated MCs is especially high at the shoulder 
region, known to be prone to rupture (Kaartinen et al., 1994b), and at the actual sites 
of erosion or rupture in myocardial infarction (Kovanen et al., 1995). At these sites, 
the proportion of degranulated MCs is approximately 85%, whereas in normal intima 
the levels are 17-28% (Kaartinen et al., 1994b, Kovanen et al., 1995). Accordingly, MC 
activation is considered to be one of the pathologic mechanisms in disease progression. 
Atherosclerotic plaques contain various components with potential to activate MCs 
however, the exact mechanisms of MC activation in atherosclerotic plaques are largely 
unkown. Potential activators of MCs in the context of atherosclerosis include inflammatory 
mediators such as oxLDL (Kelley et al., 2006), lysophosphatidic acid (Bot et al., 2013), 
complement anaphylatoxin C5a (el-Lati et al., 1994, Laine et al., 2002, Oksjoki et al., 
2007), and mediators secreted from local macrophages and T-lymphocytes (Kaartinen 
et al., 1994b, Kovanen et al., 1995). Moreover, previous study (Oksaharju et al., 2009) 
reporting activation of  MCs in vitro by bacteria shown to be present in atherosclerotic 
plaques suggests that these bacteria could act as activators of MCs in atherosclerotic 
lesions. In addition, the neuropeptide substance P induces MC activation (Bot et al., 
2010) and is expressed by nerve fibres that co-localize with MCs in human coronary 
arteries (Laine et al., 2000), thus rendering neuropeptides as potential MC activators, as 
well. Previous studies (Kovanen et al., 1998, Wang et al., 2011) also provide evidence that 
one of the potential activation pathways of MCs in atherosclerotic lesions acts through 
FcεRI (Shi et al., 2015). 
2.5.1 Mast cells promote formation of foam cells by proteolysing LDL and HDL
Upon activation, MCs are capable of releasing a wide variety of mediators that may 
contribute to atherogenesis. The increased numbers of MCs in fatty streaks (the sites 
of foam cell formation) and more advanced atherosclerotic plaques (Atkinson et al., 
1994, Kaartinen et al., 1994b, Jeziorska et al., 1997), together with studies reporting MC 
activation at sites of coronary atheroma erosion or rupture (Kaartinen et al., 1994b) 
strongly support the contention that the MC plays an important role in atherosclerosis 
both in its early and late stages. During the early events of atherosclerosis, MCs may 
contribute to increased accumulation of LDL in intima. Histamine released from locally 
activated MCs is capable of increasing endothelial permeability and thus enhancing the 
transendothelial transport of plasma LDL into tissues (Ma&Kovanen 1997). On the other 
hand, heparin PGs from exocytosed rat MC granules are capable of binding to apoB-
100 in LDL (Kokkonen&Kovanen 1987), thus facilitating proteolysis of apoB-100 by 
granule-bound chymase and CPA (Kokkonen et al., 1986). The sequential proteolysis of 
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apoB-100 by these rat MC neutral proteases results in fusion of LDL and the formation 
of larger lipid droplets on MC granules (Kokkonen&Kovanen 1989). These extracellular 
granule remnants carrying fused LDL can be taken up by macrophages (Kokkonen 1989, 
Kokkonen&Kovanen 1989) and SMCs (Wang et al., 1995) resulting in the formation of 
foam cells (Kaartinen et al., 1995, Wang et al., 1995). The contribution of MCs to foam 
cell formation is supported by the fact that in atherosclerotic lesions of carotid arteries, 
human MCs are observed in close association of macrophages and extracellular lipids, as 
well as sites of foam cell formation (Jeziorska et al., 1997). 
Mast cells may promote lipid accumulation within the arterial wall also by inhibiting 
RCT. Indeed, MC chymase is capable of degrading apoA-I in pre-β-HDL as well as 
various other apolipoproteins of HDL, namely apoA-II, apoA-IV, and apoE, and thereby 
to generate dysfunctional HDL particles with impaired ability to induce cholesterol efflux 
from macrophage foam cells (Lee et al., 1992, Lindstedt et al., 1996, Lee et al., 1999, Lee 
et al., 2002a). The mechanism seems to include the inhibition of the ABCA1-dependent 
efflux pathway (Favari et al., 2004). Furthermore, also tryptase is capable of degrading 
apolipoproteins in HDL thus blocking its function as a cholesterol acceptor (Lee et al., 
2002b). On the other hand, MC chymase and histamine are capable of inhibiting LDL 
oxidation (Lindstedt 1993, Lindstedt et al., 1993) indicating that activated MCs may also 
have antiatherogenic properties. 
2.5.2 Mast cells contribute to plaque destabilization
The various inflammatory cells within the arterial intima are capable of secreting a large 
repertoire of enzymes that may degrade collagen and other components of the extracellular 
and pericellular matrices. Thus, macrophages may secrete proforms of MMPs, which may 
be activated  by chymase and tryptase released from activated MCs. The inflammatory 
cells also secrete proinflammatory mediators capable of suppressing collagen synthesis 
by SMCs. Degradation of the pericellular matrix of SMCs by MC chymase may result in 
apoptotic death of the SMCs.  These processes will, jointly or separately, decrease collagen 
production and increase collagen degradation within atherosclerotic plaque leading to 
thinning of its fibrous cap, which again  renders the plaque prone to erosion and/or 
rupture (Kovanen 2007b). 
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AIMS OF THE STUDY
Mast cells are present in human atherosclerotic lesions, and various functions for MCs in 
atherogenesis both in its early and advanced stages have been established. Many of these 
functions have been attributed to neutral proteases that are stored in high amounts within 
MC secretory granules and released upon activation. Within the arterial intima neutral 
proteases released from the activated MCs may interact with LDL and HDL, the two 
lipoproteins crucial in the process of atherogenesis. During atherogenesis LDL and HDL 
particles are subjected to various structural and compositional modifications resulting in 
generation of LDL particles with increased proatherogenic properties and HDL particles 
with impaired antiatherogenic properties, respectively. It has become obvious that such 
processes have adverse effects on the pathogenesis of atherosclerosis. The aim of this 
thesis was to identify mechanisms by which human MCs may contribute to atherogenesis 
focusing on HDL and LDL modification by MC neutral proteases.
Specifically, the aims were to:
 1)  Identify neutral proteases that are expressed by cultured human peripheral blood 
  progenitor-derived MCs (Study I)
 2)  Analyze the ability of the various neutral proteases expressed by the cultured 
  MCs to degrade the major protein components of HDL and LDL particles, 
  namely apoA-I and apoB-100 (Study II and II)
 3)  Identify, whether the potential proteolysis of apoA-I affects its anti-inflammatory 
  properties (Study II)
 4) Identify, whether the potential proteolysis of apoB-100 in LDL affects 
  the PG-binding properties of LDL (Study III)
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Method Original publication
Cells
Isolation of human peripheral blood-derived CD34+ progenitors I, II, III
Isolation of human peripheral blood monocytes II
In vitro differentiation and culture of human mast cells I, II, III
In vitro differentiation, culture and activation of 
human monocyte-derive macrophages II
Activation of human mast cells II, III
Culture and activation of HCAECs and THP-1 cells II
Binding assays of HCAECs II
Migration of THP-1 cells II
Proteins and genes
Immunofluorescence staining (cytospin) I
Immunofluorescence staining (human coronary artery sections) III
Flow cytometry I
Enzyme-linked immunosorbent assays (ELISA) I, II
Protease activity assays I, II, III
Quantitative real-time RT-PCR I, II
NF-kB translocation II
Lipoproteins and apoA-I
HDL/LDL isolation from human plasma II, III
ApoA-I/LDL proteolysis II, III
Radioactive labeling of apoA-I/LDL II, III
LDL acetylation II
Preparation of reconstituted HDL II
Cholesterol amplex red III
Proteoglycan binding III
Circular dichroism III
Electron microscopy III
In vivo
Mouse peritonitis model II
Data
Statistical analyses I, II, III
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3 Mast cell culture and activation
3.1 Isolation of human peripheral blood-derived CD34+ progenitors 
CD34+ progenitors were enriched from mononuclear cells, which again were isolated 
from buffy coats (concentrated leukocyte suspension) prepared by the Finnish Red Cross 
Blood Service (Helsinki, Finland) from peripheral blood of voluntary blood donors. The 
use of buffy coats in the study had been approved by the Ethics Committee of the Finnish 
Red Cross. The buffy coats (40 ml) were first diluted two-fold in Dulbecco’s Phosphate 
buffered saline (DPBS) and separated into distinct phases [plasma, peripheral blood 
mononuclear cells (PBMCs), granulocytes, and erythrocytes] by centrifuging the buffy 
coat suspensions layered over Ficoll-Paque PLUS (GE Healthcare Life Sciences, Uppsala, 
Sweden) at 800 × g and 4°C for 30 min. The interface layer of the PBMCs was then collected 
and washed three times with DPBS (first at 800 x g and 4°C for 5 min, and then twice at 
250 × g and room temperature for 5 min) to remove contaminating cell types. Finally, the 
PBMCs were suspended in 50 ml of pre-chilled MACS buffer [DPBS supplemented with 
0.5% bovine serum albumin (BSA) and 2 mM ethylenediaminetetraacetic acid (EDTA)], 
and their total number was determined.
 
The CD34+ progenitor cells were next enriched from the PBMCs using positive 
immunomagnetic selection according to the instructions of the manufacturer (Miltenyi 
Biotech). Briefly, the PBMCs were simultaneously incubated with human IgG (to block 
the Fc-receptors) and with CD34 hapten antibody (to label the cell surface antigens) 
at 4ºC for 15 min. The cells were washed with pre-chilled MACS buffer, and incubated 
with CD34 anti-hapten MicroBeads at 4ºC for 15 min. After washing with MACS buffer 
(at 300 × g and room temperature for 6 min), the cells were passed through MACS 
separation column placed in a magnetic field of the MACS separator (Miltenyi Biotech). 
The magnetically labeled CD34+ cells were retained in the column, while the other cell 
types were eluted and discarded by washing the column four times with MACS buffer. 
The CD34+ cells were eluted with 5 ml of pre-chilled MACS buffer by removing the 
column from the magnetic field, after which they were washed once. Finally, the number 
of CD34+ progenitor cells was counted and the cells were resuspended in basal culture 
medium [Iscove's Modified Dulbecco's Medium (IMDM) with L-Glutamine and 25 mM 
Hepes (Biowhittaker, Lonza) supplemented with 100 U/ml penicillin (Biowhittaker, 
Lonza), 100 μg/ml streptomycin (Biowhittaker, Lonza), 100 µM β-mercaptoethanol 
(Sigma-Aldrich), 100 ng/ml recombinant human (rh)KITLG) (PeproTech, Rocky Hill, 
NJ, USA), and 20% serum substitute, BIT 9500 supplement (containing BSA, human 
recombinant insulin and human transferrin) (Stem Cell Technologies, Vancouver, British 
Columbia, Canada) at 0.5 x 106 cells/ml. Cell sedimentation during the washing steps 
was performed at 300 × g and room temperature for 6 min.
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3.2 In vitro differentiation and culture of human mast cells 
For typical experiments, the isolated CD34+ progenitor cells were grown under serum-
free conditions according to a previously published protocol (Lappalainen et al., 2007). 
The basal culture medium was supplemented sequentially with rhIL-3 (5 ng/ml), rhIL-9 
(15 ng/ml), rhIL-6 (50 ng/ml) (PeproTech, Rocky Hill, NJ, USA) as well as human low-
density lipoprotein (LDL) (10 µg/protein/ml) that was isolated as previously described 
(Havel et al., 1955, Radding&Steinberg 1960) from the plasma of healthy volunteers 
supplied by the Finnish Red Cross Blood Service. Fresh culture medium was provided 
twice a week during the first three weeks of culture, and weekly thereafter. For the first four 
weeks, the cells were cultured at 37°C in a humidified incubator flushed with a mixture 
of 5% O2, 5% CO2, and 90% N2 and thereafter under normoxic conditions (21% O2 and 
5% CO2) at 37°C. Cell viability was determined weekly by Trypan blue exclusion test. 
The cells were cultured for a total of 9 to 10 weeks, after which the cells have been shown 
to express mature MC phenotype (Lappalainen et al., 2007). The cell concentration was 
kept around 0.5 × 106 cells/ml during the whole culture period. In separate experiments 
(Study I) MCs were generated by culturing the isolated CD34+ progenitors with KITLG 
alone in the presence or absence of 10% FBS.
3.3 Activation of human mast cells
Mature MCs at a concentration of 2 x 106 MCs/ml were activated at week 9 of culture by 
incubation for 30 min with 1 µM calcium ionophore A21387 (Sigma-Aldrich) in DPBS 
in a humidified incubator at 37°C (21% O2 and 5% CO2). After incubation, the MCs were 
sedimented, and the supernatant containing the released neutral proteases referred to as 
the MC releasate was collected and stored at -80°C until further analysis. 
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4 Protease activity assays and protease inhibitors
The amounts of active neutral proteases in MC releasates were determined using specific 
protease substrates and/or inhibitors. Tryptase (β-tryptase) concentration in MC 
releasates was determined through hydrolysis of N-(p-Tosyl)-Gly-Pro-Lys-4-nitroanilide 
(GPK-4NA; Sigma-Aldrich, St Louis, Mo) by incubating the releasates for 60 minutes 
with 0.25 mM GPK-4NA in PBS containing 0.02% heparin and 0.15 mol/L NaCl at 37°C 
(pH 7.5) and measuring the increase in optical densities at 405 nm with a microplate 
reader. Recombinant human β-skin tryptase (Promega) was used to construct the 
standard curve. Chymase concentration in the MC releastes were determined through 
hydrolysis of a chymase-specific substrate, acetyl-L-Arg-Glu-Thr-Phe-4-nitroanilide 
(RETF-4NA), generously provided by Dr George Caughey (Veterans Affairs Medical 
Center, San Francisco, Calif). The substrate has been shown to be selectively hydrolyzed 
by chymase but not by cathepsin G (Raymond et al., 2009). For chymase determinations, 
MC releasates were mixed with 1 mM RETF-4NA in 0.5 mol/L Tris-HCl containing 
2 mol/L NaCl and 9% dimethyl sulfoxide (pH 8.0), and  changes in optical densities 
at 405 nm were immediately registered for 5 minutes at 30-second intervals at room 
temperature. Chymase activity in the releasates was then converted to a mass (µg) by using 
chymase-specific activity under the above-mentioned conditions. Cathepsin G levels 
in the releasates were determined through hydrolysis of N-succinyl-Ala-Ala-Pro-Phe-
4-nitroanilide (AAPF-4NA; Sigma-Aldrich). Cleavage of the substrate by chymase was 
excluded by using a peptidic inhibitor, diphenylNa-benzoxycarbonyl-L-Arg-Glu-Thr-
PheP-phosphonate (RETF-(OPh)2), generously provided by Dr Gunnar Pejler (Uppsala 
University, Uppsala, Sweden). RETF-(OPh)2 selectively inhibits chymase, while allowing 
full activity of cathepsin G (Raymond et al., 2003). For cathepsinG determinations, MC 
releasates were preincubated with 670 nM RETF-(OPh)2 in 0.1mol/L HEPES buffer 
(pH7.5) for 30 minutes on ice. The reaction was then initiated by the addition of AAPF-
4NAat a final concentration of 1.8mM, and changes in optical densities at 405 nm were 
monitored for 10 minutes at 30-second intervals at room temperature. Cathepsin G 
activity in the MC releasates was converted to a mass (µg) by using cathepsin G–specific 
activity under the above-mentioned conditions. Granzyme B concentration in the 
releasates was determined with a commercial assay according to the instructions of the 
manufacturer’s (Sigma-Aldrich). All concentrations were expressed as µg protease/ml 
releasate. In some experiments, tryptase, chymase, and CPA3 in the MC releasates were 
inhibited as follows: tryptase with 200 µg/ml leupeptin (Sigma-Aldrich), chymase with 
670 nM (RETF-(OPh)2, and CPA3 with 1 µl/100 µl Carboxypeptidase Inhibitor from 
potato tuber (Sigma-Aldrich).
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5 LDL
5.1 Proteolysis of LDL 
Human LDL (d = 1.019–1.050 g/ml) were isolated from plasma of healthy volunteers 
(supplied by the Finnish Red Cross Blood Service) by sequential ultracentrifugation in the 
presence of 3 mM EDTA, as described previously (Havel et al., 1955, Radding&Steinberg 
1960). After, isolation LDL was dialyzed against LDL buffer (150 mM NaCl, 1 mM 
EDTA, pH 7.4) and the protein concentration was determined by BCA Protein Assay 
Kit (Thermo Scientific). LDL proteolysis was induced by incubation of LDL (1 or 2 
mg/ml) with MC releasate, or alternatively with either 1.5 µg/ml recombinant human 
chymase (Sigma-Aldrich), 20 µg/ml recombinant human β-tryptase (a kind gift from Dr. 
Christian Sommerhoff), 4.5 µg/ml cathepsin G from human neutrophils (Biomol), 10 µg/
ml CPA from bovine pancreas (Sigma-Aldrich), or 0.1 µg/ml granzyme B (QuickZyme 
Biosciences) in DPBS overnight at 37°C. In some experiments plasma of three healthy 
donors was pooled prior to LDL isolation. The pooled LDL (1 mg/ml) was then incubated 
overnight with the recombinant human chymase (1.5 µg/ml) or with cathepsin G (4.5 
µg/ml) in the presence of 100 µg/ml PGs that were prepared from the intima-media of 
human aortas as previously described (Hurt-Camejo et al., 1990, Öörni et al., 1997). 
5.2 Radioactive labeling of LDL 
In some experiments, LDL was t-butoxycarbonyl-L-[3H]methionine N-hydroxy-
succinimidyl ester (Amersham Biosciences) according to the Bolton-Hunter procedure 
(Bolton&Hunter 1973). For that purpose, 100 µCi t-butoxycarbonyl-L-[3H]methionine 
N-hydroxy-succinimidyl ester (3H-reagent) per 2 mg LDL was evaporated in a glass tube 
under Nitrogen gas. Next 2 mg/ml LDL in 0.1 M Borate (pH 8.5) was incubated with the 
evaporated 3H-reagent for 30 min on ice followed by incubation of the labeling reagent 
and LDL mix with 50µl/ml of 2M glycine in 0.1M borate (pH 8.5) for 5 min on ice. 
The 3H-LDL was then dialyzed against LDL buffer 3x500 ml (1x overnight) to remove 
the unbound labeling reagent, after which the concentration of the labeled LDL was 
determined by BCA Protein Assay kit. Finally, the activity of the 3H-LDL was determined 
by liquid scintillation counting. For that purpose, 10 µl of the 3H-LDL was mixed with 3 
ml of scintillation liquid and the resultant photon emissions (following absorption by the 
scintillator of the energy transferred to the solvent molecules by the β-particles emitted 
from the 3H-LDL) were recorded using β-counter. 
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6 Statistical analyses
Statistical analyses were performed with the GraphPad Prism software, version 6 
(GraphPad Software, Inc., La Jolla, CA, USA) and SPSS for Windows software, version 
20 (SPSS Inc., Chicago, Illinois, USA). The nonparametric Kruskall-Wallis test with 
Dunn's multiple comparisons correction was used to compare the groups. Differences 
in continuous variables were assessed by analysis of variance or linear regression, where 
appropriate. p<0.05 was considered statistically significant. Correlations were investigated 
by calculation of Pearson’s coefficient of correlation. The data are expressed as means ± 
SEM or ± SD. 
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7 Neutral protease expression in cultured human mast cells (I)
 
7.1 In vitro differentiation of human mast cells as a tool to study 
      neutral protease expression (I)
Human cell culture systems are powerful tools to study protease expression in MCs and 
have become available after identification of factors promoting survival of MCs in vitro. 
To obtain human MCs for in vitro studies of protease expression three approaches are 
available: 1) to use human MC lines, namely HMC-1, LAD2, or LUVA (Butterfield et 
al., 1988, Kirshenbaum et al., 2003, Laidlaw et al., 2011); 2) to isolate MCs from human 
tissues, such as the lungs, intestinal mucosa, and skin (Kulka&Metcalfe 2010, Lorentz et 
al., 2015); and 3) to differentiate MCs in vitro from hematopoietic progenitor cells present 
in human cord blood, peripheral blood of adult subjects, bone marrow, or fetal liver (Irani 
et al., 1992a, Kirshenbaum et al., 1992, Mitsui et al., 1993, Saito et al., 1996, Xia et al., 1997, 
Toru et al., 1998, Kinoshita et al., 1999, Ahn et al., 2000, Kambe et al., 2000, Kambe et al., 
2001, Shimizu et al., 2002, Moon et al., 2003, Wang et al., 2006, Lappalainen et al., 2007). 
Regarding option 1, the MC lines represent MCs of relatively immature differentiation 
stages that express proteases only at low levels (Guhl et al., 2010). Regarding option 2, 
only a limited number of MCs can be isolated from tissues, and additionally tissue MCs 
represent terminally differentiated cells, which do not usually divide in culture. Instead, 
differentiation of MCs in vitro from their progenitors ultimately yields high numbers of 
MCs, and allows characterization of protease expression during MC development. Thus 
option 3 was a method of choice when we set out to characterize protease expression in 
human MCs.
Couple of years prior to our study a protocol for generating human MCs in vitro had been 
developed at our laboratory (Lappalainen et al., 2007) to gradually move on from studies 
using rat MCs to studies using human MCs. The protocol utilizes CD34+ progenitor 
cells present in peripheral blood as a source of MC precursors and has the advantage 
of resulting in generation of high numbers of functionally mature MCs in a relatively 
short period of time under well-defined serum-free conditions. Furthermore, buffy coats 
of healthy volunteers as the source of the CD34+ progenitors guarantee a continuous 
availability of the progenitors for MC differentiation without major ethical concerns.
 
At the time, we began to characterize protease expression in human MCs several 
neutral proteases had been identified within their granules. These were chymase, CPA3, 
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cathepsin G, granzyme B, and tryptases derived from the TPSAB1, TPSB2, TPSD1, and 
TPSG1 genes (Caughey 2016). However, virtually all studies that had examined protease 
expression during MC differentiation had focused solely on tryptase and/or chymase 
expression, whereas no studies of CPA3, cathepsin G, and granzyme B expression during 
MC development had been reported. Given the number of known human MC proteases and 
studies that had described the presence within human tissues of MCs with novel protease 
phenotype, namely tryptase+ and CPA3+ (Abonia et al., 2010, Dougherty et al., 2010) 
we hypothesized that heterogeneity of human MCs protease phenotypes could be more 
complex than initially suggested. Furthermore, the expression of the whole set of human 
MC neutral proteases had never been described within the same human MC, and we were 
intrigued to examine, whether these neutral proteases were expressed in the cultured MCs 
generated according to the protocol previously developed at our laboratory. Yet another 
question that we were interested in was the potential developmental relationship of the 
MCT and MCTC subtypes, a topic that had shared a vast interest among the scientific field 
of MC biology but which had remained a matter of dispute. To be able to best answer these 
questions we found it important to include all human MC neutral proteases identified until 
then in our study of protease expression in developing human MCs.
7.2 Cultured human mast cells express the whole set of studied 
       neutral proteases (I)
We began our studies by generating human MCs from CD34+ peripheral blood-derived 
progenitors under serum-free conditions with KITLG and sequential addition of IL-
3, IL-9, and IL-6 according to the protocol previously developed at our laboratory 
(Lappalainen et al., 2007). At each week, a fraction of the cultured MCs was analyzed 
for expression of tryptase, chymase, CPA3, cathepsin G, and granzyme B at the levels 
of both mRNA and protein. As shown in Study I, Fig 1; middle and Fig. 2 the cultured 
MCs expressed transcripts for the various tryptase isoforms, namely TPSAB1/TPSB2 
(α-/β1-tryptase/β2-/β3-tryptase), TPSD1 (δ-tryptase) and TPSG1 (γ-tryptase), as well 
as for chymase, CPA3, cathepsin G, and granzyme B. Previously, cultured human MCs 
had been shown to express transcripts for β-tryptase, chymase, CPA3, and cathepsin 
G (Saito et al., 2001). Furthermore, α- (Miller et al., 1990), δ- (Wang et al., 2002), and 
γ-tryptases (Wong et al., 1999) as well as granzyme B (Strik et al., 2007) had been 
identified at the transcriptional level in human MCs. Our study is however the first to 
demonstrate transcriptional expression of all the above mentioned neutral proteases in a 
single homogeneous population of MCs.
Protease phenotypes of cells can be studied by two major techniques: light microscopy of 
immunohisto-/immunocytochemically stained tissue sections/cells and flow cytometry. 
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Of these, flow cytometry is far more sensitive in detecting proteins (Ahn et al., 2000) 
and was thus a method of choice to analyze protease expression at the protein level. At 
the time, we initiated our study, 4 human MC phenotypes within human tissues had 
been described: 1) tryptase+, chymase- (MCT) (Irani et al, 1986), tryptase+, chymase+, 
CPA3+, cathepsin G+ (Irani et al. 1986), 3) tryptase-, chymase+ (MCC) (Weidner et 
al., 1993), and 4) tryptase+, CPA3+, chymase- (Abonia et al., 2010; Dougherty et al., 
2010) (Irani et al., 1986, Schechter et al., 1990, Irani et al., 1991, Weidner&Austen 1993, 
Abonia et al., 2010, Dougherty et al., 2010). Additionally, in human culture systems, the 
development of tryptase+, chymase- MC (MCT), tryptase+, chymase+ MC (MCTC), 
and chymase+, tryptase- MC (MCC) had been demonstrated (Irani et al., 1992a, Li et 
al., 1996, Toru et al., 1998, Kinoshita et al., 1999, Ahn et al., 2000, Shimizu et al., 2002, 
Lappalainen et al., 2007). Study I, Figure 1; left shows that the MCs generated in the 
presence of KITLG and sequentially added IL-3, IL-9, and IL-6 expressed protein for all 
studied neutral proteases, namely tryptase, chymase, CPA3, cathepsin G, and granzyme 
B. The expression was detected from the earliest week of analyses (week 1) to the time the 
study was terminated (week 9-10). During the early weeks of culture the percentages of 
protease positive MCs between the individual neutral proteases differed slightly, however 
the expression of the studied proteases appeared to follow a common pattern. Thus, the 
percentages of MCs positive for each individual protease progressively increased during 
early weeks of culture, and reached a plateau at week 6, at which time practically all MCs 
in the culture of all donors were positive for the complete panel of the studied proteases. 
Importantly, for each studied neutral protease a single continuous population of MCs 
expressing that protease at various levels (based on mean fluorescence intensity, MFI) 
was always observed, without any indication of discrete protease-positive and protease-
negative MC subpopulations in the culture. This indicates development from CD34+ 
peripheral blood-derived progenitors of single population of MCs with a novel tryptase+, 
chymase+, CPA3+, cathepsin G+, and granzyme B+ phenotype.
7.2.1 KITLG triggers the expression of human mast cell neutral proteases (I)
Differentiation in vitro of MC populations mainly of the MCT subtype in the presence 
of KITLG alone initially led to conclusion that KITLG alone might be insufficient to 
promote development of the MCTC subtype (Irani et al., 1992b, Mitsui et al., 1993). 
During the following years Ahn and coworkers however demonstrated that human cord 
blood-derived MC progenitors developed into MCTC exclusively even when cultured 
under KITLG alone (Ahn et al., 2000). Furthermore, the study of Ahn and coworkers 
(Ahn et al., 2000) as well as that of Toru and coworkes (Toru et al., 1998) had provided 
evidence that chymase expression is somewhat cytokine dependent, which prompted 
us to raise a question whether the neutral protease expression by the MCs we had 
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differentiated depended on the cytokine combination (IL-3, IL-6, and IL-9) we had used. 
To investigate this possibility, the CD34+ peripheral blood-derived progenitors were next 
cultured under KITLG alone, followed by analysis of tryptase and chymase expression by 
flow cytometry. Flow cytometric analysis showed that the percentage of tryptase-positive 
MCs of all MCs (defined as high KIT expression) at week 1 was 94% ± 2% and 96% ± 
3% (n=4) when the CD34+ progenitors were cultured under KITLG alone and under 
KITLG in the presence of IL-3, respectively. The corresponding percentage of chymase-
positive MCs of all MCs at week 1 was 25% ± 12% and 60% ± 27% (n=4). At week 3, 
virtually all cells in both cultures were positive for tryptase and chymase (Study I, Fig. 3). 
Importantly, flow cytometric analyses always showed a single homogeneous population of 
MCs expressing tryptase and chymase at various levels but not discrete chymase-negative 
subpopulation, regardless of the presence or absence of the cytokines, indicating that 
circulating human MC progenitors have not been precommitted to develop into MCT. 
The finding is in line with the study of Ahn and coworkers (Ahn et al., 2000) suggesting 
that all human MCs are capable of producing chymase, in contrast to what had previously 
been suggested (Irani et al., 1992a). The apparent discrepancy of the conclusions may be 
explained by the difference in the culture period. Indeed, human MCs, which contain 
tryptase but little or no chymase, are capable of upregulating their chymase expression 
during incubation with IL-4 and IL-6, resulting in a change of the phenotype from MCT 
to MCTC (Toru et al., 1998; Kinoshita et al., 1999). Irani and coworkers (Irani et al., 
1992a) did not observe phenotypic switch of MCT to MCTC within 30 days, and thereby 
concluded that human MCT and MCTC derive from two distinct progenitors with 
irreversibly precommitted protease phenotype. However, depending on the source of the 
progenitor cells the phenotypic switch from MCT to MCTC may require an exceptionally 
long period of culture, even months (Kinoshita et al., 1999). Ahn and coworkers (Ahn 
et al., 2000) cultured cells for 8-13 weeks at which time all in vitro differentiated human 
MCs expressed chymase.
Importantly, MCs that were generated under KITLG alone also contained CPA3, 
cathepsin G, and granzyme B (Study I, Fig. 4), suggesting a novel role for KITLG as 
a common inducer of neutral protease expression in human MCs. Binding of KITLG 
to its receptor, KIT, recruits downstream signaling molecules including the basic-helix-
loop-helix leucine zipper transcription factor called microphthalmia transcription factor 
(MITF) (Phung et al., 2011). Studies both in human (Lee et al., 2010) and mice (Pejler et 
al., 2007) provide evidence that MITF might be a key target of KITLG in the regulation 
of MC protease expression. 
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8 Proteolysis of apoA-I and apoB-100 by human mast cell 
   neutral proteases (II & III)
During atherogenesis both HDL and LDL undergo various structural and compositional 
modifications that adversely affect their functionality. Factors capable of such 
modifications are various cell- and plasma-derived extracellular proteases present in the 
inflamed atherosclerotic plaques. The repertoire of such proteases include members of 
the MMP family, (Lee-Rueckert&Kovanen 2011) plasmin, kallikrein, and thrombin (Piha 
et al., 1995) and lysosomal cathepsins D, F, K, and S (Sukhova et al., 1998, Hakala et al., 
2003, Öörni et al., 2004, Plihtari et al., 2010). Furthermore, upon activation and ensuing 
degranulation MCs release neutral serine proteases, among them chymase, which is 
capable of cleaving the various apolipoproteins present in HDL as well as apoB-100 
of LDL (Kokkonen et al., 1986, Lee-Rueckert&Kovanen 2011). However, since human 
tissue MCs are known to contain several other neutral proteases, namely tryptase, CPA3, 
cathepsin G and granzyme B (Caughey 2016), which were expressed by our in vitro 
differentiated MCs, we were intrigued to study the ability of these proteases to cleave the 
major protein components of HDL and LDL, namely apoA-I and apoB-100, respectively. 
8.1 Chymase and cathepsin G generate C-terminally truncated 
       apoA-I and apoB-100 (II & III)
We began our studies by activating cultured human MCs to degranulate and thus to 
release their neutral granule proteases in the culture medium to obtain MC releasate 
for the in vitro studies. As shown in Study I (Fig. 1, right panel), the cultured MCs 
accumulated the various neutral proteases during their maturation at least up to 9 weeks 
of culture, at which point the human MCs were activated to degranulate for obtaining 
conditioned medium (from now on referred to as MC releasate) for the experiments. 
The MC releasates contained 11.2 ± 5.8 µg/ml of tryptase, 1.3 ± 0.4 µg/ml of chymase, 
3.2 ± 1.2 µg/ml of cathepsin G, and 0.09 ± 0.1 µg/ml of granzyme B (n = 5 donors in 
duplicate experiments), as determined by activity assays used to measure the amount of 
enzymatically active neutral proteases released to the culture medium.
The MC releasate was then collected and incubated with LDL and lipid-free apoA-I. 
Treatment with MC releasate led to proteolysis of both apoA-I and apoB-100. Indeed, 
MC releasate induced loss of apoA-I C-terminal reactivity in a concentration-dependent 
manner (Study II;Figure 1C, right) as well as extensive proteolysis of apoB-100 of LDL 
(Study III, Figure 1A-C). To further analyze the individual contribution of each of the 
5 released proteases to apoA-I and apoB-100 degradation we used specific protease 
inhibitors and/or individual neutral proteases.   As shown in Study II, Figure I in the 
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online-only Data Supplement, inhibition of chymase with RETF-(OPh)2, an inhibitor 
that selectively inhibits chymase without affecting cathepsin G (Raymond et al., 2003), 
almost completely blocked apoA-I degradation, whereas inhibition of both chymase 
and cathepsin G completely blocked it. In contrast, inhibition of tryptase, CPA3, or 
granzyme B had only minor if any effect on degradation of apoA-I. The results thus 
indicate that among the neutral proteases released by activated human MCs, chymase is 
the main protease responsible for the C-terminal cleavage of apoA-I. Chymase-treatment 
completely depleted the full-length apoA-I and generated a large-sized polypeptide which 
had lost immunoreactivity against a monoclonal antibody recognizing a C-terminal 
epitope covering the amino acid residues 211–220. Instead, chymase did not modify 
immunoreactivity of apoA-I against a monoclonal antibody specific for the N-terminal 
region (amino acids 2–8) (Study II,Figure 1C, left), an observation in agreement with a 
previous report (Lee-Rueckert et al., 2008).
When we set out to characterize the proteolysis of apoB-100 of LDL by human MC neutral 
proteases, we had reason to believe in the destruction potential of chymase since both rat 
and human chymase had previously been shown to degrade apoB-100 (Kokkonen et al., 
1986; Plihtari et al., 2010). Thus, were we more interested in the proteolytic activity of 
the other human MC neutral proteases on apoB-100. A particular interest focused on 
cathepsin G, due to its ability to cleave many peptide and protein targets that are also 
cleaved by chymase [reviewed in (Pejler et al., 2007)]. Indeed, we found that cathepsin G 
efficiently fragmented apoB-100 of LDL (Study III, Fig. 1 A-C). Incubation with cathepsin 
G yielded release from 3H-labelled LDL of TCA soluble fragments that represented 12.9 
± 0.9% of the apoB-100 of LDL, whereas incubation with chymase yielded release of 4.2 
± 0.1%, followed by tryptase (3.3 ± 0.1%), and CPA (2.5 ± 0.3%). In these conditions, 
granzyme B was practically unable to fragment apoB-100 of LDL (Study III, Fig 1A). 
When all proteases, except cathepsin G, had been inhibited with specific inhibitors, MC 
releasate resulted in release of about 10.7 ± 2.3% of TCA-soluble fragments, a finding 
in line with the results obtained with purified cathepsin G. Furthermore, treatment of 
LDL with cathepsin G led to almost total loss of C-terminal reactivity of apoB-100, as 
indicated by ELISA (Study III, Fig. 1B) that specifically detected the apoB-100 but not 
the C-terminally truncated apoB-48 that contains the 48% of the N-terminal sequence 
of apoB-100. Taken together, chymase and cathepsin G generate C-terminally truncated 
apoA-I and apoB-100, respectively. 
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8.2 Effects of chymase on the anti-inflammatory actions of apoA-I on
       endothelial cells and leukocytes
MC chymase had previously been shown to efficiently cleave lipid-free apoA-I and to 
deplete preβ-HDL particles, and so to block their ability to promote cholesterol efflux from 
macrophage foam cells in vitro and in vivo (Lee-Rueckert et al., 2011). Current data provide 
evidence that by regulating cellular cholesterol homeostasis, apoA-I and HDL can also 
regulate inflammatory responses in various cell types present within the arterial intima 
[reviwed in (Mineo&Shaul 2013)]. Since apoA-I and HDL have direct anti-inflammatory 
actions on ECs and leukocytes [reviewed in (Mineo&Shaul 2012)] both of which influence 
vascular health and disease, we were interested, whether cleavage of apoA-I by human MC 
chymase also affected its anti-inflammatory effects on these cells. 
8.2.1 Chymase-dependent proteolysis impairs the ability of apoA-I to bind to and 
          to suppress NF-κB-dependent proinflammatory responses in HCACs (II)
Endothelial activation plays crucial role in atherogenesis especially in its early stages by 
inducing expression of chemotactic factors such as VCAM-1 and ICAM-1, which recruit 
immune cells, mostly monocytes to arterial vessel wall (Rao et al., 2007). Both lipid free 
apoA-I and HDL have been shown to exert anti-inflammatory effects for activated ECs of 
human, bovine and murin origin in vitro (D'Souza et al., 2010, Van Linthout et al., 2011, 
Cheng et al., 2012). In rabbits acute vascular inflammation and VCAM-1 and ICAM-1 
expression in the aortic endothelium are blunted by HDL in vivo (Patel et al., 2010), 
however glycated apoA-I derived from in vitro modification or from hyperglycemic 
individuals, impaired this anti-inflammatory property of apoA-I/HDL (Nobecourt et 
al., 2010). We began our studies by investigating whether cleavage by chymase affects 
the ability of apoA-I to suppress TNF-α-dependent VCAM-1 expression in human 
coronary artery endothelial cells (HCAECs). As shown in Study II, Fig. 1A, upregulation 
of VCAM-1 in TNF-α activated HCAECs was partially prevented by preincubation of the 
HCAECs with apoA-I (Study II, Fig. 1A). However chymase-treated apoA-I totally failed 
to suppress the TNF-α-dependent upregulation of VCAM-1 expression (Study II, Fig. 
1B), a finding consistent with the observation of impaired anti-inflammatory action of 
glycated apoA-I on endothelial activation in vivo (Nobecourt et al., 2010). Consequently, 
chymase-treated apoA-I was also unable to inhibit THP-1 cells from adhering to and 
transmigrating across the HCAECs (Study II, Fig. 3C). Furthermore, chymase-treated 
apoA-I had an impaired ability to inhibit induction of COX-2, IL-6, and IL-8 expression 
in TNF-α activated HCAECs (Study II, Fig.  4A–D). 
Previous studies have provided evidence that ABCA1 is not only involved in cholesterol 
metabolism, but also modulate the anti-inflammatory response of cells to apoA-I 
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[reviewed in (Mineo&Shaul 2012, 2013)]. In ECs, apoA-I inhibits adhesion molecule 
expression via interaction with ABCA1 (Prosser et al., 2012). Furthermore, the anti-
inflammatory and antioxidant effects of the apoA-I mimetic peptide 5A are mediated via 
ABCA1 and NF-κB signaling pathways in HCAECs (Tabet et al., 2010). Thus, interaction 
of apoA-I to ABCA1 appears to essentially mediate anti-inflammatory actions of apoA-I 
in ECs. As shown in Study II, Figure   3A chymase-dependent proteolysis impaired the 
ability of apoA-I to attenuate activation in HCAECs of NF-κB (Study II, Figure   3A) 
and severely blunted (≥80%) the high-affinity binding of apoA-I to HCAECs    (Study 
II, Figure 3B), suggesting that the C-terminal domain that was depleted by chymase, is 
required for binding of apoA-I to HCAECs and for subsequent inhibition of the NF-κB 
signaling pathway. The importance of  C-terminal domain for apoA-I binding to ECs is 
further supported by a previous study reporting severly impaired binding of C-terminal 
deletion mutations of apoA-I to bovine ECs (Ohnsorg et al., 2011).
8.2.2 Chymase-dependent proteolysis impairs the ability of apoA-I to inhibit 
          expression of proinflammatory genes and to induce cholesterol efflux 
          in macrophage foam cells  (II)
In addition to inhibiting EC activation, HDL/apoA-I also directly attenuates the activation 
of monocytes/macrophages [reviewed in (Mineo&Shaul 2012)]. In macrophages LPS 
induced expression of inflammatory cytokines is attenuated by apoA-I via ABCA1 (Tang 
et al., 2009), whereas silencing of ABCA1 abolishes such inhibitory effect of apoA-I 
(Yin et al., 2011). Moreover, apoA-I exerts anti-inflammatory effects on peptidoglycan 
polysaccharide-activated human macrophages in an ABCA1-dependent manner (Wu et 
al., 2014). These and other data suggest an anti-inflammatory role for ABCA1 pathway in 
macrophages. Considering that in macrophage foam cells ABCA1-mediated cholesterol 
efflux pathway is predominating (Adorni et al., 2007, Larrede et al., 2009), a dual regulatory 
function for ABCA1 in macrophage lipid metabolism and inflammation appears to 
exist (Schmitz et al., 1999). Regarding the effect of chymase-treated apoA-I on its ability 
to interact with macrophages, we found that chymase-treated apoA-I had impaired 
ability to suppress LPS-induced upregulation of TNF-α, IL-1β, IL-6, and IL-8 in human 
monocyte-derived macrophage foam cells of both GM-macrophage and M-macrophage 
subtypes (Study II, Fig. 4E-L). Furthermore, in consistent with previous studies (Favari 
et al., 2004, Lee-Rueckert et al., 2008) the chymase-dependent proteolysis of apoA-I also 
decreased the ability of apoA-I to induce cholesterol efflux from macrophage foam cells 
(Study II, Fig. 4M). Amino acid residues 220-231 of apoA-I have previously been shown 
to be necessary for functional interactions between the apoA-I and ABCA1 and thus to 
be required for lipid efflux in vitro and HDL biogenesis in vivo (Chroni et al., 2003). Thus, 
it is likely that the present finding of the decreased ability of the C-terminally truncated 
apoA-I generated by chymase to suppress proinflammatory response in LPS-activated 
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macrophages reflects impaired interaction between the truncated apoA-I and ACBA1 in 
the macrophages. Thus, a failure to bind to macrophage ABCA1 appears to be a molecular 
link between impaired anti-atherogenic effects of chymase-treated apoA-I, namely 
reduced anti-inflammatory and cholesterol efflux and capacities. This concept is further 
supported by previous findings of impaired cholesterol efflux ability and concomitant 
reduction in anti-inflammatory properties of oxidized (Pirillo et al., 2010) and glycated 
apoA-I (Hoang et al., 2007, Nobecourt et al., 2010).
8.2.3 Proteolysis by chymase reduces anti-inflammatory properties of 
          apoA-I in vivo (II)
ApoA-I inhibits inflammatory responses also in vivo in experimental animals such 
as in mouse subjected to LPS-induced inflammation (Yan et al., 2006, Li et al., 2008). 
We used this well-established mouse model to examine whether chymase-dependent 
proteolysis would also affect the anti-inflammatory properties of lipid-free apoA-I. 
LPS administration remarkably increased the levels of two proinflammatory cytokines, 
namely TNF-α and IL-1β, whereas concurrent treatment of mice with both LPS and 
lipid-free apoA-I significantly reduced the level of both of these cytokines  (Study II, 
Figure5 A&B). In contrast, concurrent treatment of mice with LPS and chymase-treated 
apoA-I failed to significantly reduce the levels of either TNF-α or IL-1β, indicating that 
the chymase-dependent proteolysis impaired the anti-inflammatory properties of apoA-I 
in vivo  (Study II, Figure 5 A&B). Further studies comparing the ability of apoA-I and 
chymase-treated apoA-I to neutralize endotoxin activity, a mechanism by which both 
HDL and apoA-I have been demonstrated to exert their anti-inflammatory properties in 
vivo, suggested that impaired ability of chymase-treated apoA-I to inhibit LPS-induced 
inflammation resulted from a total loss of its ability to neutralize endotoxin (Study II, 
Figure 5C).
8.3 Cathepsin G and chymase generate fused LDL particles with 
       increased PG binding affinity (III)
LDL fusion is a processes important in atherogenesis promoting both extracellular and 
intracellular lipid accumulation within the arterial wall (Öörni et al., 2000). Proteolysis 
of apoB-100 has previously been described to induce fusion of LDL particles (Paananen 
et al., 1995, Piha et al., 1995), which is suggested to be based on disruption of the 
particle integrity due to proteolysis of apoB-100 on LDL and subsequent development of 
unstable LDL particles prone to fuse (Kovanen&Kokkonen 1991). Apparently however, 
mere fragmentation of apoB-100 is not sufficient to induce LDL particle fusion. Indeed, 
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proteolytic degradation of LDL by trypsin (Piha et al., 1995) and α-chymotrypsin 
(Paananen et al., 1995, Piha et al., 1995) resulted in LDL particle fusion, whereas 
proteolytic fragmentation of LDL with plasmin, kallikrein, and thrombin did not (Piha 
et al., 1995). The inability of the latter three enzymes to induce fusion of LDL was linked 
to their ability to only fragment but not to release the fragments of apoB-100 from LDL 
(Piha et al., 1995). We found that treatment of LDL with either cathepsin G, chymase, 
or MC releasate, resulted in formation of enlarged LDL particles compared with native 
LDL (Study III, Fig 4A), and the average-sized fusion particles (29.5 ± 0.70 nm, 30.3 ± 
0.60 nm, and 27.0 ± 0.32 nm for MC releasate-, cathepsin G-, and chymase-modified 
LDL, respectively) appeared to result from fusion of 2-3 LDL proteolyzed LDL particles 
(Study III, Fig. 4C). However, the largest particles that were observed were generated by 
cathepsin G and had diameters of about 100 nm and had thus been generated by fusion 
of about 100 of the averaged-sized 22-nm LDL particles.
In consistent with the previous studies showing that fusion of LDL particles results in 
increased affinity to PGs (Öörni et al., 1998, Hakala et al., 2001, Plihtari et al., 2010), 
we found that proteolysis of LDL with cathepsin G and MC releasate, and to a lesser 
extent with chymase, significantly increased the affinity of the LDL particles to human 
aortic PGs when compared to native LDL (Study III, Fig. 2A). Indeed, the number of 
LDL bound to PGs was almost 4-fold when LDL had been treated with cathepsin G or 
with MC releasate and 2-fold when LDL was treated with chymase compared to native 
LDL. The binding of LDL to human atherosclerotic plaques was evaluated by incubating 
fluorescently labeled LDL, both native and cathepsin G-treated with frozen tissue sections 
of human carotid plaques. We found that treatment of LDL with cathepsin G increased 
remarkably the binding of LDL to the plaques, as indicated by differences in fluorescence 
intensities (Study III, Fig. 2B & C). Furthermore, enzymatic digestion of CS caused a 
remarkable reduction in the binding of the cathepsin G-treated LDL (Study III, Fig. 2C 
& D), indicating that CS of the ECM play an important role in mediating the binding of 
LDL to the atherosclerotic plaques.
Potential underlying mechanisms of the increased PG-binding of the proteolyzed LDL 
include conformational changes in the apoB-100 secondary structure, which may had 
exposed cryptic domains for PG-binding (Paananen et al., 1995). Indeed, although native 
LDL appears to contain a single crucial PG-binding site, site B (Boren et al., 1998a), 
delipidated apoB-100 has been shown to contain several potential heparin-binding sites 
and an additional PG-binding site, designated as site A (residues 3147-3157) (Olsson 
et al., 1997). PLA2 modification of LDL has been reported to induce conformational 
changes in apoB-100 rendering the site A functionally available. Consequently the site 
A co-operated with the site B in PG-binding resulting in increased PG-binding of the 
modified LDL (Flood et al., 2004). We used circular dichroism (CD) to analyze whether 
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proteolysis of LDL induced conformational changes in the secondary structure of apoB-
100. The far ultraviolet spectra of proteolyzed LDL (Study III, Fig 3A) had similar shapes 
compared to native LDL but showed a slight decrease in CD intensity, indicating that 
proteolysis of LDL, especially with cathepsin G results in conformational changes of 
apoB-100. The difference between the CD spectra of cathepsin G-treated and native LDL 
is shown in Study III, Fig. 3B. Furthermore, it was previously reported that proteolytical 
fusion of LDL increases the number of basic domains of apoB-100 known to be associated 
with PG-binding in the fused particles (Paananen et al., 1995), providing a plausible 
explanation for the increased PG-binding of the proteolyzed LDL observed in the present 
study.
8.4 Mast cells are the major cathepsin G containing cell types in stable
       atherosclerotic lesions (III)
Classically, expression of cathepsin G has been associated with neutrophils and MCs, 
however based on a previous immunohistochemical study also macrophages appear 
to contain cathepsin G (Wang et al., 2014). We evaluated the proportion of cathepsin 
G containing MCs in stable atherosclerotic lesions of human coronary arteries by 
double immunofluorescence staining using specific antibodies against cathepsin G and 
tryptase. As shown in Study III, Fig. 5A-D, the majority (69 %) of the cells that stained 
positive for cathepsin G also stained positive for tryptase, indicating the presence of 
cathepsin G-containing MCs in the atherosclerotic plaques. The finding is in line with 
a previous study from our laboratory that reported MCs to represent on average 73% of 
all cathepsin G-containing cells in the coronary atherosclerotic plaques (Mäyränpää et 
al., 2006). In consistent with the immunofluorescence data, cathepsin G expression in 
the atherosclerotic plaques of coronary arteries strongly correlated with the expression 
of MC chymase and tryptase, and to a lesser extent with CD68, which is expressed 
mainly by monocyte/macrophages but also by MCs. On the contrary no correlation was 
found between lesional cathepsin G and neutrophil proteinase 3 (Study III, Fig. 5E-H). 
Taken together, MCs appear to be the major cathepsin G-containing cell type in stable 
atherosclerotic plaques of coronary arteries.
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The use of neutral protease concentrations based on in vitro differentiated MCs may bias 
the relative contribution of the various neutral proteases on the determined proteolytic-
dependent processes. However, we have used neutral protease concentrations that were 
found in the MC releasates, which reflects the ratio of the neutral protease contents 
within the cultured human MCs. 
The use of a mouse peritonitis model weakens atherosclerosis-specific interpretation of 
the results. On the other hand, it provides a relevant link between in vitro and in vivo 
studies of the anti-inflammatory effects of chymase-treated apoA-I. 
The inclusion of all three arterial wall layers in the isolation of RNA from coronaries 
weakens an intima-specific interpretation of the results. On the other hand the data 
represent the totality of inflammatory cells throughout the arterial wall layers during 
atherosclerosis. Another limitation is the partial degradation of RNA detected in the 
coronary samples. The degradation may be due to disease processes (necrosis), tissue 
preparation and storage such as delay in snap-freezing and the warming of the sample 
during intensive homogenization required for the tough consistency of the vascular 
tissue (Fleige&Pfaffl 2006). 
Unspecific staining of the coronary and carotid samples may yield false negative or false 
positive results. Such stainings may be due to use of inappropriate antibodies, storage 
and preparation of the samples (delay before snap-feezing, inappropriate fixative), and 
warming of the frozen tissue while cutting. However, negative and positive controls were 
used to evaluate the stainings and the actual stainings were analyzed with a pathologist.
LIMITATIONS OF THE STUDY
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CONCLUSIONS AND FUTURE PERSPECTIVES
Human MCs with different protease phenotypes can be found within human tissue their 
relative abundance changing with anatomic localizations and disease stage. Considering 
that activated MCs are capable of releasing high amounts of neutral proteases, the 
protease phenotype is likely to have a pronounced effect on the disease setting. Activated 
MCs are present in increased numbers in human atherosclerotic lesions, where they 
have potential to interact with lipoprotein particles entering the arterial intima. This 
thesis focused on proteolytic modifications of apoA-I and apoB-100, the major protein 
components of HDL and LDL particles, respectively by human MC neutral proteases, 
and ensuing effects on the anti-inflammatory properties of the proteolyzed apoA-I and 
PG-binding properties of the proteolyzed LDL. 
In Study I, we describe development of cultured human MCs expressing neutral proteases 
chymase, CPA3, cathepsin G, granzyme B, and tryptases derived from the TPSAB1, 
TPSB2, TPSD1, and TPSG1/PRSS31 genes. This is the first study to describe human 
MCs of tryptase+, chymase+, CPA3+, cathepsin G+ and granzyme B+ phenotype. By 
showing development of a single homogeneous population of MCs with a uniform 
protease phenotype, and by indicating KITLG as the common inducer of the expression 
of all the above mentioned neutral proteases, the study suggests that human MCs have 
the potential to express various neutral proteases. Thus, the protease phenotype of a 
particular MC appears to reflect a functional state the MC has assumed under the local 
microenvironment, and is a subject to change along with changes in the surrounding 
microenvironment. 
Study II identifies chymase-dependent C-terminal cleavage of apoA-I as a novel 
mechanism that leads to loss of its anti-inflammatory properties, being the first study to 
demonstrate involvement of a pathophysiologically relevant protease in the regulation of 
several anti-inflammatory functions of apoA-I. In study III we found a novel mechanism 
by which human MCs may contribute to LDL retention within the arterial wall, that is, 
by generating, via cathepsin G, proteolyzed LDL particles with increased PG-binding 
affinity, a property which is linked to the atherogeneicity of LDL. Thus, Study II and 
III suggest novel mechanism by which activated MCs may contribute to atherogenesis 
(Figure 7). 
The clinical relevance of the present findings remains to be elucidated. However, since 
LDL retention by subendothelial PGs is an important driving force in atherogenesis 
(Boren&Williams 2016), determining molecules that affect LDL retention may be 
of clinical importance. To date LDL-C lowering drugs remains as the cornerstone 
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for the pharmaceutical prevention and treatment for cardiovascular disease and 
ongoing therapeutic improvements include even more aggressive lowering of plasma 
lipoproteins and treatment initiation at earlier age (Bergheanu et al., 2017). However, 
because accumulation of LDL within the vessel wall is recognized as a critical step in 
the pathogenesis of atherosclerosis, inhibition of the physical interaction between LDL 
and the arterial wall might offer new approaches to delay or reduce the formation of 
atherosclerotic lesions. As various factors are known to influence the PG-binding and 
retention of atherogenic lipoproteins within the arterial wall, the process offers a myriad 
of potential pharmaceutical targets that might lead to new therapeutic approaches 
against ACVD. Furthermore, since, atherosclerotic lesions contain various proteases 
capable of generating C-terminally truncated apoA-I, proteolytic inactivation of apoA-I 
is likely. Thus, regarding targeting of inflamed protease-rich atherosclerotic lesions with 
apoA-I, infusions of protease-resistant apoA-I mimetic peptides might be appropriate 
approach. Finally, better understanding of the factors that are capable of regulating 
MC protease phenotypes in the local microenvironments is required for a successful 
design of treatment strategies aimed at combatting MC-associated diseases, in which the 
various neutral proteases released by activated MCs contribute to the development and 
progression of the disease-specific pathologies.
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Figure 7. Proteolysis of LDL and apoA-I within the arterial intima by neutral proteases released from acti-
vated human MCs. LDL and nascent HDL/apoA-I enter the arterial intima and become proteolyzed by neutral 
proteases released from activated human MCs. Proteolysis of apoB-100 of LDL by cathepsin G and chymase 
(1) results in fusion of LDL particles generating enlarged lipid particles (2) with increased PG-binding property 
(3). The physical interaction between LDL and PGs hinders the exit of LDL particles from the arterial wall thus 
promoting intramural lipid accumulation. The retained LDL particles activate the ECs inducing expression of 
VCAM-1 and proinflammatory genes (4). Proteolysis by chymase generates C-terminally truncated apoA-I (5) 
with impaired ability of the apoA-I to bind to ECs and thus to suppress the upregulated expression of VCAM-1 
and proinflammatory genes in the ECs (6). ApoA-I is also unable to inhibit the subsequent adhesion of mo-
nocytes to the activated ECs and their migration across the endothelium (7). Within the intima, the monocytes 
differentiate into macrophages, which uptake the retained and modified LDL particles and transform into lipid 
laden foam cells (8). The proteolyzed apoA-I is unable to interact with macrophage ABCA1, which results in 
reduced ability of the apoA-I to induce cholesterol efflux from the macrophage foam cells (9). The retained and 
modified LDL particles activate macrophages inducing upregulation of proinflammatory genes, a process which 
the proteolyzed apoA-I is unable to inhibit (10). Eventually the foam cells die contributing to formation of a 
necrotic lipid core. Thus, by releasing neutral proteases capable of degrading apoA-I of HDL and apoB-100 of 
LDL within the arterial intima, human MCs may promote lipid accumulation and inflammation, two processes 
critical in the pathogenesis of atherosclerosis.
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